EP3692144A1 - Use of p38 inhibitors to reduce expression of dux4 - Google Patents

Use of p38 inhibitors to reduce expression of dux4

Info

Publication number
EP3692144A1
EP3692144A1 EP18797227.8A EP18797227A EP3692144A1 EP 3692144 A1 EP3692144 A1 EP 3692144A1 EP 18797227 A EP18797227 A EP 18797227A EP 3692144 A1 EP3692144 A1 EP 3692144A1
Authority
EP
European Patent Office
Prior art keywords
dux4
protein
cell
expression
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18797227.8A
Other languages
German (de)
English (en)
French (fr)
Inventor
Angela Marie CACACE
Luis Gustavo Alejandro ROJAS SOTO
Lorin A. Thompson, Iii
Owen Brendan Wallace
Lucienne V. RONCO
Ning SHEN
Aaron Nakwon Chang
Alan Scott Robertson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fulcrum Therapeutics Inc
Original Assignee
Fulcrum Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fulcrum Therapeutics Inc filed Critical Fulcrum Therapeutics Inc
Publication of EP3692144A1 publication Critical patent/EP3692144A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11024—Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Definitions

  • the present invention relates to compositions and methods of inhibiting p38 kinase to reduce gene and protein expression of DUX4 and downstream genes regulated by DUX4.
  • the present invention further relates to methods for treating subjects with disease and disorders associated with increased expression of DUX4 or expression of an aberrant form of DUX4, such as Facioscapulohumeral muscular dystrophy (FSHD).
  • FSHD Facioscapulohumeral muscular dystrophy
  • the muscular dystrophies are a group of more than 30 different genetic diseases characterized by progressive weakness and degeneration of the skeletal muscles that control movement. Some forms of MD occur in infancy or childhood, while others may not appear until middle age or older.
  • the various MD diseases differ in terms of the distribution and extent of muscle weakness (some forms of MD also affect cardiac muscle), age of onset, rate of progression, and pattern of inheritance.
  • Facioscapulohumeral muscular dystrophy is the third most common form of muscular dystrophy and affects approximately 1 in 15,000 people worldwide.
  • FSHD is caused by genetic mutations resulting in the epigenetic derepression of the DUX4 gene, which makes this disease unique among muscular dystrophies.
  • FSHD's primary manifestations are weakness and wasting of muscles of the face, shoulder girdle, upper arms, and trunk, and impacts lower extremities in more severe cases.
  • FSHDl representing about 95% of FSHD cases reported, is associated with deletions of macrosatellite D4Z4 repeats in the subtelomeric region of chromosome 4q35, leaving 1-10 D4Z4 repeats (reviewed in Tawil et. al., 2014).
  • FSHD2 is caused by mutations in Structural Maintenance of Chromosomes Flexible Hinge Domain Containing 1 gene (SMCHD1) on chromosome 18 (reviewed in van der Maarel et. al., 2007). Both FSHDl and FSHD2 mutations lead to loss of repression at the 4q35 D4Z4 repeat array, allowing aberrant transcription in muscle of a full-length form of Double homeobox 4, DUX4, mRNA (DUX4-fl), which encodes the double homeobox 4 (DUX4) transcription factor (Tawil et. al., 2014). DUX4-fl RNA isoforms found associated with FSHD vary only in the 3' untranslated region and have no identified functional distinction.
  • FIGS. 1A and IB show expression of DUX4 protein and RNA in FSHD myotubes.
  • FIG. 1A includes micrographs of FSHD myotubes stained using an antibody that binds DUX4 protein and/or 4',6-diamidino-2-phenylindole (DAPI; to detect nuclei). Mature FSHD myotubes showed actin striations in culture (not shown) and expressed DUX4 protein in discrete sets of nuclei contained within a differentiated myotube (FIG. 1A).
  • FIG. IB is a graph showing relative expression of DUX4 mRNA in FSHD myotubes and myotubes from an isogenic wild type (healthy) control.
  • FIG. 2 is a graph showing mRNA expression of the indicated DUX4 regulated genes in wild type myotubes treated with DMSO, or FSHD myotubes treated with FTX-2 or DMSO.
  • the bars from left to right correlate to wild type myotubes treated with DMSO, FSHD myotubes treated with DMSO, and FSHD myotubes treated with FTX-2 (£>tZY ⁇ -targeted ASO).
  • FIGS. 3 A- 3C show reduction oiMBD3L2 mRNA in FSHD myotubes treated with Z ) £ZY ⁇ -targeted ASOs.
  • FIG. 3A is a graph showing grouped plate quality control data comparing MBD3L2 expression in FSHD myotubes treated with DMSO control or 1 ⁇ D£ZY ⁇ -targeted ASOs, and healthy normal isogenic wild-type myotubes (WT).
  • FIG. 3B is a graph showing dose- dependent reduction oiMBD3L2 mRNA expression in FSHD myotubes treated with different dilutions of the D£ZY ⁇ -targeted ASO (FTX-2).
  • FIG. 3C shows plate-based assay statistics comparing MBD3L2 signal in FSHD myotubes treated with DMSO to Z)£ZY ⁇ -targeted ASOs or wild-type myotubes treated with DMSO.
  • FIGS. 4A-4D are graphs showing expression levels of MBD3L2 mRNA and TOG mRNA in FSHD myotubes treated with the indicated ⁇ 38 ⁇ / ⁇ inhibitors relative to treatment with DMSO control.
  • the ⁇ 38 ⁇ / ⁇ inhibitors included SB 239063 (FIG. 4A), VX-702 (FIG. 4B), Pamapimod (FIG. 4C), and TAK-715 (FIG. 4D).
  • the structures of the inhibitors are also provided.
  • FIGS. 5A and 5B show data from FSHD myotubes treated with Pamapimod.
  • FIG. 5A is a graph showing that dose-dependent reduction in DUX4-fl mRNA (filled circles) and MBD3L2 mRNA (open circles).
  • FIG. 5B shows micrographs of FSHD myotubes treated with either DMSO or Pamapimod.
  • FIGS. 6A-6C are graphs showing mRNA levels ⁇ 14 (FIG. 6A) and MBD3L2 (FIG. 6B and FIG. 6C) in FSHD myotubes treated with siRNAs targeting p38a MAPK14 (siMAPK14 85 and siMAPK14 86; FIG. 6A and FIG. 6B) or treated with p38a kinase (MAPK14 and DUX4 pLAM) Cas9/sgRNA RNPs (FIG. 6C), as compared to non-targeting control (NT CTRL).
  • NT CTRL non-targeting control
  • FIG. 7 is a graph showing expression levels of DUX4 protein, MBD3L2 mRNA, and p-HSP27 protein in FSHD myotubes following treatment with increasing dosages of FTX- 1821 (structure shown), as a percentage of DMSO control treatment levels. Bars represent standard deviation.
  • FIGS. 8A and 8B show the effect of FTX-1821 on myotube formation.
  • FIG. 8A provides representative images of morphology of immortalized FSHD myotubes obtained after treatment with vehicle (DMSO) or the indicated concentrations of FTX-1821, and staining with antibodies against MHC and DAPI (nuclear stain).
  • FIG. 8B is a graph showing quantification of nuclei in myotubes, as defined by MHC staining, after treatment with FTX- 1821 at concentrations tested. Bars represent standard deviation of three replicates.
  • FIGS. 9A and 9B show the results of apoptosis assays in FSHD myotubes in vitro.
  • FIG. 9A provides micrographs of FSHD myotubes stained for active caspase-3 (as a marker of apoptosis) or DAPI. Apoptosis was detected in a sporadic manner in a subset of myotubes in culture as shown by white circles in the left panel and in the magnified region to the right.
  • FIG. 9B is a graph showing quantification of active caspase-3 signal in FSHD myotubes treated with the indicated concentrations of FTX 1821.
  • FIGS. 10A and 10B illustrate the identification of genes downregulated in FSHD myotubes by FTX- 1821.
  • FIG. 1 OA is a heatmap, which illustrates differentially expressed genes identified by RNA-seq profiling. Three replicates for each condition were analyzed by RNA-seq and genes were clustered by the direction and intensity of change as indicated. The color bar indicates the normalized changes observed, e.g., genes that were downregulated by FTX- 1821 are enriched in samples treated with only DMSO. Down-regulated genes are listed in FIG. 10A.
  • FIG. 10A illustrates the identification of genes downregulated in FSHD myotubes by FTX- 1821.
  • 10B is a graph showing the normalized expression level reads of the DUX4 target genes that were downregulated upon treatment with FTX- 1821 in wild type cells treated with vehicle control DMSO, FSHD cells treated with DMSO, or FSHD cells treated with FTX- 1821.
  • FIG. 11 is a graph showing mRNA expression levels by qRT-PCR of the DUX4 target gene, MBD3L2 (normalized to POLR2A), in myotubes derived from four distinct FSHD patient myoblast lines, FTCE-016, -020, -197, -196 and two wild type (WT) control lines, following the indicated treatment with DMSO vehicle control, FTX-1821 or FTX-839.
  • MBD3L2 normalized to POLR2A
  • FIGS. 12A and 12B provide information on various p38 inhibitors.
  • FIG. 12A is a table of data summarizing pharmacology for the indicated p38a and ⁇ inhibitors, including IC50 for reducing MBD3L2 expression in FSHD cells. Comparable MBD3L2 IC50 values are shown, indicating inhibition of DUX4 downstream gene expression in FSHD myotubes across a broad structural panel of p38a and ⁇ inhibitors reported to have similar enzyme potencies. These data indicate that p38 inhibition result in DUX4 target gene, MBD3L2, reduction IC50 values in the range of -6-68 nM.
  • FIG. 12B provides the compound structures of the p38 inhibitors listed in FIG. 12A.
  • FIG. 13 is a table of various cell lines utilized in "clinical trial in a dish," which shows diversity of genotypes, and includes both primary and immortalized lines, as well as FSHD 1 and FSHD2 patient lines.
  • FIGS. 14A and 14B are graphs showing MBD3L2 mRNA expression normalized to POLR2A (by qRT-PCR) (FIG. 14A) and apoptosis as measured by cleaved caspase-3 (FIG. 14B) determined in nine FSHD1 and three FSHD2 patient myotubes (listed in Table 2, FIG. 14B contains only two FSHD2 cell lines) following treatment with FTX-1821, FTX-839, or DMSO vehicle control.
  • FIG. 15 is a graph showing the time course of plasma exposure, trapezius muscle exposure and p38 target engagement (Phosphorylated p38a: Total p38a Ratio) in the rat following oral administration of 0.3 mg/kg FTX-1821.
  • FIG. 16 is a graph showing MBD3L2 mRNA levels in A4 and C6 xenografted TA muscles.
  • FIG. 17 is a graph showing phosphor/total MC2 ratio in mouse trapezius muscles following treatment with vehicle control or p38 inhibitor, FTX-2865.
  • FIG. 18 is a graph showing MBD3L2 mRNA levels in C6 xenografted TA muscles following treatment with vehicle control or p38 inhibitor, FTX-2865.
  • the present disclosure provides methods of reducing the expression a DUX4-fl mRNA, a DUX4 polypeptide, or a polypeptide encoded by a downstream target gene of DUX4, in cells, comprising contacting the cells with an agent that results in a reduction of active p38 protein in the cell, thereby reducing expression the DUX4 polypeptide or the polypeptide encoded by the downstream target gene of DUX4.
  • agents may be practiced using a variety of different types of agents, and for modulating a variety of different biological processes in the cell, as well as for treating subjects for diseases associated with aberrant DUX4 expression, such as FSHD.
  • the cell is a muscle cell, optionally a terminally differentiated muscle cell.
  • the cell has an increased expression level of the DUX4-fl mRNA, the DUX4 polypeptide, or the polypeptide encoded by the downstream target gene, as compared to the expression level of the DUX4-fl mRNA, the DUX4 polypeptide, or the polypeptide encoded by the downstream target gene, in a control cell, e.g., a cell obtained from a healthy subject.
  • the increased expression level of the DUX4-fl mRNA, the DUX4 polypeptide, or the polypeptide encoded by the downstream target gene is due to reduced repression at a D4Z4 locus in the cell.
  • the cell is associated with facioscapulohumeral muscular dystrophy (FSHD), e.g., it was obtained from a subject diagnosed with FSHD or is present within a subject diagnosed with FSHD.
  • FSHD facioscapulohumeral muscular dystrophy
  • the cell comprises a deletion of one or more macrosatellite D4Z4 repeats in the subtelomeric region of chromosome 4q35, optionally wherein the cell comprises ⁇ 7 macrosatellite D4Z4 repeats in the subtelomeric region of chromosome 4q35.
  • the cell comprises one or more mutations in a Structural Maintenance Of Chromosomes Flexible Hinge Domain Containing 1 (SMCHD1) gene.
  • the cell comprises at least one non-deleted 4qA allele.
  • the agent inhibits the expression or activity, or reduces the amount, of the p38 protein, wherein the activity is optionally kinase activity.
  • the agent inhibits the expression of the p38 protein.
  • the agent binds a polynucleotide encoding the p38 protein, or binds an antisense polynucleotide thereof.
  • the agent comprises or consists of a nucleic acid, optionally a DNA, RNA, gRNA, shRNA, siRNA, or antisense oligonucleotide.
  • the agent inhibits the activity of the p38 protein.
  • the agent binds the p38 protein.
  • the agent comprises or consists of a polypeptide, optionally a protein, a peptide, a protein mimetic, a peptidomimetic, or an antibody or functional fragment thereof.
  • the agent comprises a small molecule, optionally a small organic molecule or a small inorganic molecule.
  • the downstream target gene is RFPL2, CCNA1, SLC34A2, TPRX1, KHDC1L, ZSCAN4, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15 or ZNF280A.
  • the expression or the activity of the p38 protein, or the amount of the p38 protein is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%.
  • the present disclosure provides a method of treating or preventing a disease or disorder associated with increased expression of a DUX4-fl mRNA, a DUX4 protein, or a polypeptide encoded by a downstream target gene of DUX4, in a subject in need thereof, comprising providing to the subject a pharmaceutical composition comprising an agent that results in a reduction in the amount of active p38 protein in one or more tissue of the subject, thereby reducing expression of the DUX4-fl mR A, the DUX4 protein, or the polypeptide encoding the downstream target gene in one or more tissue of the subject.
  • the disease or disorder is a facioscapulohumeral muscular dystrophy (FSHD), optionally FSHD1 or FSHD2.
  • the subject comprises reduced repression at a D4Z4 locus.
  • the subject comprises a deletion of one or more macrosatellite D4Z4 repeats in the subtelomeric region of chromosome 4q35, optionally wherein the cell comprises ⁇ 7 macrosatellite D4Z4 repeats in the subtelomeric region of chromosome 4q35.
  • the subject comprises one or more mutations in a Structural Maintenance Of Chromosomes Flexible Hinge Domain Containing 1 (SMCHD1) gene.
  • SMCHD1 Structural Maintenance Of Chromosomes Flexible Hinge Domain Containing 1
  • the subject comprises at least one non- deleted 4qA allele.
  • the expression or the activity of, or the amount of, the p38 protein is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% in a muscle tissue of the subject.
  • the method decreases muscle degeneration in the subject.
  • the method reduces apoptosis of muscle cells in the subject.
  • the muscle tissue is terminally differentiated.
  • the pharmaceutical composition is provided to the subject parenterally or orally.
  • the pharmaceutical composition is provided to a muscle tissue of the subject, optionally parenterally or intramuscularly.
  • the method further comprises providing to the subject a second agent or therapy for treating the disease or disorder associated with increased expression of a DUX4 protein, or a polypeptide encoded by a downstream target gene of DUX4.
  • the present disclosure also provides a unit dosage form of a pharmaceutical composition
  • a pharmaceutical composition comprising an agent that results in a reduction in the amount of active p38 protein in a cell, and a pharmaceutically acceptable carrier, diluent or excipient, wherein the unit dosage form is effective to reduce expression or activity of a DUX4-fl mRNA, a DUX4 polypeptide, or a polypeptide encoded by a downstream target gene of DUX4, in one or more cell or tissue in a subject to whom the unit dosage form is administered.
  • the agent binds the DUX4 polypeptide or binds a polynucleotide encoding the DUX4 polypeptide.
  • the agent comprises or consists of a nucleic acid, optionally a DNA, RNA, gRNA, shRNA, siRNA, or antisense oligonucleotide.
  • the agent comprises or consists of a polypeptide, optionally a protein, a peptide, a protein mimetic, a peptidomimetic, or an antibody or functional fragment thereof.
  • the agent comprises a small molecule, optionally an organic molecule or an inorganic molecule.
  • the tissue is muscle tissue, optionally wherein the tissue comprises cells comprising a mutation associated with
  • FSHD facioscapulohumeral muscular dystrophy
  • the present disclosure provides a method of reducing apoptosis of a cell, e.g., a muscle cell, comprising contacting the cell with an agent that results in a reduction in the amount of active p38 protein in the cell, optionally wherein the muscle cell is terminally differentiated, thereby reducing expression of a DUX4-fl mRNA, a DUX4 protein, or a polypeptide encoded by a downstream target gene of DUX4, in the cell.
  • the cell has an increased expression level of the DUX4-fl mRNA, the DUX4 polypeptide, or the polypeptide encoded by the downstream target gene, as compared to the expression level of the DUX4 polypeptide, or the polypeptide encoded by the downstream target gene, in a control cell.
  • the increased expression level of the DUX4-fl mRNA, the DUX4 polypeptide, or the polypeptide encoded by the downstream target gene is due to reduced repression at a D4Z4 locus in the cell.
  • the cell comprises one or more mutations associated with FSHD.
  • the agent inhibits the expression of the p38 protein, optionally wherein the agent binds a polynucleotide encoding the p38 protein, or an antisense polynucleotide thereof.
  • the agent comprises or consists of a nucleic acid, optionally a DNA, RNA, shRNA, siRNA, or antisense oligonucleotide, e.g., which targets p38.
  • the agent inhibits the activity of the p38 protein, optionally wherein the agent binds the p38 protein.
  • the agent comprises or consists of a polypeptide, optionally a protein, a peptide, a protein mimetic, a
  • the agent comprises a small molecule, optionally a small organic molecule or a small inorganic molecule.
  • the expression or the activity of the p38 protein, the DUX4 protein, or the polypeptide encoded by the DUX4 downstream gene is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%.
  • the method reduces apoptosis of muscle cells in a muscle tissue at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% as compared to a control, e.g., an untreated cell.
  • the agent reduces expression of DUX4 or the downstream target gene.
  • the agent binds a p38 protein, e.g., p38-ot or ⁇ 38- ⁇ , or binds a polynucleotide encoding the p38 protein, e.g., p38-ot or ⁇ 38- ⁇ , or an antisense polynucleotide thereof.
  • the agent comprises or consists of: a nucleic acid, optionally a DNA, RNA, shRNA, siR A, CRISPR gRNA, or antisense oligonucleotide.
  • the agent comprises or consists of: a polypeptide, optionally a protein, a peptide, a protein mimetic, a
  • the agent comprises: a small molecule, optionally an organic molecule or an inorganic molecule.
  • the downstream target gene is RFPL2, CCNA1, SLC34A2, TPRX l, KHDC IL, ZSCAN4, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF 15 or ZNF280A.
  • the downstream target gene is MBD3L2, ZSCAN4, LEUTX, PRAMEF2, TRIM43, or KHDCIL.
  • the agent binds a p38 protein, e.g., p38-ot or ⁇ 38- ⁇ , or binds a polynucleotide encoding a p38 protein e.g., p38-ot or ⁇ 38- ⁇ .
  • the agent comprises or consists of: a nucleic acid, optionally a DNA, RNA, shRNA, siRNA, mRNA, CRISPR gRNA, modified mRNA, morpholino, or antisense oligonucleotide.
  • the mRNA or modified mRNA encodes an antibody or a functional fragment thereof.
  • the agent comprises or consists of: a polypeptide, optionally a protein, a peptide, a protein mimetic, a
  • the agent comprises or consists of a gene therapy vector, e.g., a viral vector comprising a nucleic acid sequence encoding a polynucleotide or polypeptide inhibitor of p38, e.g., p38-ot or p38- ⁇ , or other target.
  • the agent comprises or consists of a small molecule, optionally an organic molecule or an inorganic molecule.
  • the downstream target is RFPL2, CCNA1, SLC34A2, TPRXl, KHDCIL, ZSCAN4,
  • the downstream target gene is MBD3L2, ZSCAN4, LEUTX, PRAMEF2, TRIM43, or KHDCIL. In some embodiments, the downstream target gene is CCNA1.
  • the present invention is based, in part, on the discovery that inhibition of p38 kinase, e.g., p38-ot, results in reduced expression of DUX4 and downstream genes regulated by DUX4. Accordingly, the invention includes methods and compositions related to using an inhibitor of p38, e.g., p38-ot, (alone or in combination with another agent) to reduce the expression and/or activity levels of DUX4 and/or any of its downstream target genes, e.g., in the treatment or prevention of diseases associated with aberrant DUX4 expression, such as FSHD, a type of muscular dystrophy.
  • an inhibitor of p38 e.g., p38-ot
  • any of its downstream target genes e.g., in the treatment or prevention of diseases associated with aberrant DUX4 expression, such as FSHD, a type of muscular dystrophy.
  • This may be accomplished in a variety of ways, e.g., reducing expression of the DUX4-fl mRNA, reducing expression of the DUX4 protein, inhibiting DUX4 protein activity; CRISPR genome editing, and/or inducing degradation of the DUX4 protein.
  • the muscular dystrophies are a diverse group of genetic diseases that cause progressive weakness of the body's muscles. Some types of muscular dystrophy will present symptoms in early childhood, while other types will appear in adulthood. Different muscle groups also may be affected depending on the type of muscular dystrophy. See, e.g., Isin Dalkilic and Louis M Kunkel. Nearly 30 genes are known to give rise to various forms of muscular dystrophy, which differ in age of onset, severity, and muscle groups affected. The number of genes identified increases each year, adding to our understanding as well as revealing the overall complexity of the pathogenesis of these diseases.
  • DMD Duchenne Muscular Dystrophy
  • FSHD Facioscapulohumeral dystrophy
  • Similarities between DMD and FSHD include that both are genetic diseases and symptoms include muscle loss with muscle weakness leading to disability (therefore both DMD and FSHD are grouped in the large category of muscular dystrophies, which means muscle degeneration).
  • DMD and FSHD have very different etiology and disease diagnosis (dystrophin loss in DMD vs expression of DUX4- myotoxin in FSHD).
  • DMD mutations in the DMD gene (>2000 known) result in dysfunctional or missing dystrophin.
  • FSHD the disease is due to overexpression of the DUX4 gene in muscle tissue; it is not due to point mutations in the gene (DUX4 protein is expressed when the number of D4Z4 repeats in the DUX4 gene is between 1 and 8, or when repression is lost at the D4Z4 by mutations in other silencing machinery).
  • Other differences include that only skeletal muscle is involved in FSHD, whereas both skeletal and cardiac muscle are affected in DMD; the diaphragm is involved in DMD but not FSHD; generally there is childhood onset in DMD but adult/adolescent onset in FSHD; and onset with ambulatory involvement in DMD but onset with face and proximal arm/shoulders in FSHD.
  • FSHD also has an unusual pathology, and it is unique among muscular dystrophies in that its development requires both genetic and epigenetic conditions.
  • the genetic condition is the presence of a complete DUX4 gene.
  • the DUX4 gene is a retrogene normally expressed in germ line and early embryonic cells, but it is repressed by D4Z4 repeat-induced silencing in adult tissues (Ehrlich and Lacey, 2012).
  • Each D4Z4 element contains a promoter and the DUX4 ORF, but lacks a polyadenylation signal (PAS), resulting in rapid DUX4 mR A degradation.
  • PAS polyadenylation signal
  • transcripts initiated in the distal D4Z4 unit on a 4qA permissive allele extend outside of the repeat array and reach a PAS in the flanking pLAM sequence (reviewed in Tawil et al., 2014; Himeda et al, 2015).
  • the resulting poly-A tail stabilizes the DUX4 mR As and allows for their translation into a protein that is not normally expressed in healthy muscle and is toxic to skeletal muscle function.
  • DME1 DUX4 myogenic enhancer 1
  • DME2 DME2
  • FSHD1, FSHD2 stages in early development as well as germline formation stages appear to confer a transcriptionally permissive conformation to D4Z4 chromatin. This is evidenced by changes in histone modification, partial but variable hypomethylation of D4Z4 in FSHD 1, and more extensive hypomethylation in FSHD2 (Himeda et al., 2015).
  • D4Z4 hypomethylation does not suffice for the disease, since there is an absence of muscular dystrophy symptoms in patients with ICF (immunodeficiency, centromeric region instability and facial anomalies), a rare, unrelated DNA hypomethylation-associated disease in which D4Z4 is strongly hypomethylated (OMIM Entry - # 614069).
  • DUX4 is a homeobox transcription factor protein, and expression of DUX4 in muscle induces a transcriptional program leading to expression of downstream genes and protein products that are not normally expressed in skeletal muscle.
  • DUX4 expression results in the induction of several germline genes in FSHD skeletal muscles and in transfected cells (Y ao et al, 2014; Ehrlich and Lacey, 2012). Many of these novel transcripts are expressed in FSHD muscle cells but not in control muscle cells (Y ao et al, 2014; Homma et al., 2015; Shadle et al., 2017; Bosnakovski et al, 2014).
  • DUX4 pathological activation leads to a large gene expression deregulation cascade in muscle, which causes the disease (Yao et al., 2014; Homma et al, 2015; Shadle et al., 2017; Bosnakovski et al., 2014).
  • Endogenous (in the FSHD myofiber) and forced DUX4 expression in muscle cells is toxic, leads to apoptosis and oxidative stress, and interferes with myogenesis and sarcomere function (Rickard et al, 2015; Homma et al, 2015; Bosnokovski et al., 2014; Tawil et al, 2014; Himeda et al., 2015).
  • Clinical heterogeneity in both disease progression and age of onset can be accounted for, in part, by epigenetic instability leading to progressive changes in DUX4 transcription.
  • DNA hypomethylation and permissive DUX4 transcription is exemplified by the high clinical severity observed in patients who inherited combined FSHD1 and 2 defects (reviewed in Tawil et al., 2014; van der Maarel et al., 2007). Clinical heterogeneity is also explained by differences in the severity of D4Z4 repeat shortening, with more severe phenotype and younger age at onset in patients with shorter repeats (1-3) compared to patients with less severely contracted repeats (4-7).
  • DUX4 is now recognized as the cause of the pathology of FSHD, since activation of its target genes is the main molecular signature in FSHD muscle (Reviewed in Tawil et al., 2014; Himeda et al., 2015).
  • Major downstream target genes are members of highly homologous gene families that are clustered spatially on chromosomes, including PRAMEF (preferentially expressed in melanoma), TRIM (tripartite motif-containing), MBDL (methyl- CpG binding protein-like), ZSCAN (zinc finger and SCAN domain containing) and RFPL (ret-finger protein-like) families (Geng et al., 2012; Yao et al., 2014; Shadle et al, 2017; Ehrlich and Lacey, 2012; Tawil et al., 2014; van der Maarel et al., 2007). Discrimination between FSHD and control skeletal muscle can be made using ZSCAN4, LEUTX,
  • PRAMEF2 TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1,
  • PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF 15, ZNF280A etc. described in but not limited to Yao et al., 2014; Shadle et al., 2017; Ehrlich and Lacey, 2012).
  • Annotated chemical probes were screened to identify disease -modifying small molecule drug targets that reduce DUX4 expression in FSHD myotubes. These screens identified multiple chemical scaffolds that inhibit the activity of p38 mitogen-activated protein kinase alpha (MAPK14 or p38ot). As described in the accompanying Examples, it has been shown that knockdown of the MAPK14 gene using small interfering RNA (siRNA) technology or CRISPR-mediated genome editing with specific guide RNA's (gRNAs) that selectively target the alpha isoform of p38 kinase also reduces DUX4 and DUX4-related downstream gene expression in FSHD myotubes.
  • siRNA small interfering RNA
  • gRNAs specific guide RNA's
  • p38 kinase inhibitor small molecules reduce the expression of DUX4 and related downstream genes, thereby impacting pathophysiology of the FSHD disease process, including reducing apoptotic cell death.
  • p38-mediated DUX4 reduction would be expected to impact downstream inflammatory, fatty infiltration, and fibrotic processes in FSHD.
  • the p38 kinase pathway can be activated by a number of external stimuli, including pro-inflammatory cytokines and cellular stress, leading to activation of the dual-specificity MAPK kinases MKK3 and MKK6. Activation of MKK3 and MKK6, which in turn phosphorylate p38 in its activation loop, trigger downstream phosphorylation events.
  • p38a MAPK is known to play critical roles in skeletal muscle biology, specifically in abrogating proliferating myoblasts to differentiation and subsequently fusion to form multinucleated myotubes. Treatment of muscular dystrophy patients that are constitutive ly undergoing processes of degeneration and regeneration with p38a inhibitors would not be obvious.
  • Complete knockout (KO) of p38a is embryonically lethal. Embryonic rescue allows for survival of pups to a few days postnatal and isolation of satellite cells to study myogenic precursors lacking p38a. Myoblasts completely lacking p38a express significantly less critical differentiation genes and show severe deficits in fusion. Histology of P2 pups show significantly increased cycling satellite cells and a left-shifted fiber distribution.
  • p38 has been shown to regulate gene expression during myogenesis.
  • ⁇ 38 ⁇ has been shown to be required for myogenesis using both specific gene knock out and conditional knock out approaches (Cuenda et.al., 2007; Kerin et.al, 2006; Aouadi et.al, 2006).
  • selective inhibitors of p38a and ⁇ avoid p38y-related impact to myogenesis.
  • p38 is activated during myogenesis, and that inhibition of p38a and ⁇ by molecules exemplified herein, including FTX-839, FTX-1821, etc., profoundly reduces DUX4 expression and its downstream gene program in FSHD myotubes (data exemplified herein).
  • p38a appears to directly regulate DUX4 expression by impacting the activity of critical myogenic enhancers required for pathologic DUX4 expression at the level of the mutated D4Z4 locus with shorter repeats (FSHD1) or SMCHD1 mutations (FSHD2) or when repression is lost by other mechanisms in the muscle of FSHD patients.
  • the term “approximately” or “about” refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).
  • administering refers herein to introducing an agent or composition into a subject or contacting an agent or composition with a cell and/or tissue.
  • the disclosure includes a method for reducing the expression or activity of a DUX4 gene, mRNA, or polypeptide, or for reducing the expression or activity of a DUX4 downstream gene or polypeptide, including but not limited to any of those disclosed herein, in a cell, tissue, organ, or subject.
  • the DUX4 mRNA is DUX4-fl.
  • the term "DUX4 downstream gene” refers to a gene that is transcriptionally activated (i.e., its expression is increased) by DUX4, and the term “DUX4 downstream polypeptide” refers to the encoded polypeptide.
  • the DUX4 downstream gene is selected from those shown in FIG. 10A.
  • the methods disclosed herein may be practiced in vitro or in vivo, and in certain embodiments, the methods comprise contacting a cell, tissue, organ or subject with a p38 inhibitor, resulting in a reduced amount of active p38 protein in the cell, tissue, organ or subject.
  • p38 inhibitor may refer to any agents that results in a reduced amount of active p38 protein in the cell, tissue, organ, or subject.
  • the amount of active p38 protein in a cell may be reduced via a variety of means, including but not limited to reducing the total amount of p38 protein or inhibiting one or more activity of the p38 protein.
  • a p38 inhibitor may inhibit the expression of a p38 gene, a p38 mRNA, or a p38 protein, and/or a p38 inhibitor may inhibit a biological activity of a p38 protein.
  • the biological activity is kinase activity.
  • a p38 inhibitor may competitively bind to the ATP-binding site of p38 MAPK and inhibit its kinase activity, or it may allosterically block the kinase activity of the p38 MAPK.
  • a p38 inhibitor causes increased degradation of a p38 protein.
  • the p38 gene or p38 protein is a mammalian p38 gene or mammalian p38 protein, e.g., a human p38 gene or human p38 protein, e.g., a human p38-ot (MAPK14) or ⁇ 38- ⁇ (MAPK1 1) gene or protein.
  • a human p38 gene or human p38 protein e.g., a human p38-ot (MAPK14) or ⁇ 38- ⁇ (MAPK1 1) gene or protein.
  • p38 MAP Kinase also called RK or CSBP (Cytokinin Specific Binding Protein)
  • p38 MAP Kinases also called RK or CSBP (Cytokinin Specific Binding Protein)
  • p38 MAP kinases p38-ot (MAPK14), - ⁇ (MAPK1 1), - ⁇ (MAPK 12 / ERK6), and - ⁇ (MAPK 13 / SAPK4
  • p38 inhibitor inhibits p38-ot (MAPK14) or ⁇ 38- ⁇ (MAPK11), e.g., human versions of these genes or proteins.
  • the targeted p38 protein comprises the amino acid sequence set forth below or disclosed in GenBank accession NP_001306.1 for p38 kinase (mitogen- activated protein kinase 14 isoform 1, homo sapiens):
  • the targeted p38 gene, cDNA, mRNA or coding sequence comprises the p38-ot nucleic acid sequence set forth below or disclosed in GenBank accession NM_001315.2, or a complement thereof:
  • the targeted p38 protein comprises the amino acid sequence set forth below or disclosed in GenBank accession NP_002742.3 for p38 kinase (mitogen- activated protein kinase 11 isoform 1, homo sapiens):
  • the targeted p38 gene, cDNA, mRNA or coding sequence comprises the ⁇ 38- ⁇ nucleic acid sequence set forth below or disclosed in GenBank accession NM_002751.6, or a complement thereof:
  • AAAAAAAAAAAAAAAA SEQ ID NO: 4
  • methods disclosed herein comprising contacting a cell, tissue, organ, or subject with a p38 inhibitor, are practiced to inhibit or decrease the expression or activity of DUX4 or one or more DUX4 downstream genes.
  • the DUX4 or DUX4 downstream gene is a human gene.
  • the DUX4 double homeobox 4 (Homo sapiens) gene may comprise the nucleotide sequence set forth below or disclosed in GenBank accession NG_034189.2, or a complement thereof:
  • the DUX4 double homeobox 4 [Homo sapiens] mRNA gene may comprise the nucleotide sequence set forth below or disclosed in GenBank accession NM_001293798.2, or a complement thereof:
  • the DUX4 polypeptide sequence is as set forth below or disclosed in GenBank accession NP_001280727.1 :
  • Genomic nucleotide accession NC_000019.10 (7049340..7051735)
  • Methods of determining the expression level of p38, DUX4, or a DUX4 downstream gene or polypeptide in a biological sample, e.g., tissue, are known in the art and include, e.g., RT-PCR and FACS.
  • a method of reducing the expression of a DUX4 mRNA e.g., DUX4-fl
  • the agent inhibits the expression or activity of a p38 protein.
  • the agent causes increased degradation of a p38 protein, e.g., p38-ot and/or ⁇ 38- ⁇ .
  • the cell or tissue is contacted with an amount of the agent effective to reduce the expression or activity of a DUX4 polypeptide, or a polypeptide encoded by a downstream target gene of DUX4, in the cell or tissue.
  • the cell or tissue is contacted with an amount of the agent effective to reduce the amount of active p38 protein in the cell or tissue.
  • the cells are muscle cells.
  • the cells are terminally differentiated, e.g., terminally differentiated muscle cells.
  • the cells have an increased expression level of the DUX4 polypeptide, or the polypeptide encoded by the downstream target gene, as compared to the expression level in a control cell.
  • the cells are associated with facioscapulohumeral muscular dystrophy (FSHD), e.g., FSHD l or FSHD2.
  • FSHD facioscapulohumeral muscular dystrophy
  • the cells may be derived from or obtained from cells or tissue from a subject diagnosed with FSHD. Methods disclosed herein may be practiced in vitro or in vivo.
  • the disclosure provides a method of reducing apoptosis of a cell or tissue, comprising contacting the cell or tissue with an agent that inhibits the expression or activity of a p38 protein (also referred to herein as a p38 inhibitor), e.g., an inhibitor of p38-ot and/or ⁇ 38- ⁇ .
  • a p38 inhibitor also referred to herein as a p38 inhibitor
  • the cell or tissue is contacted with an amount of the agent effective to reduce the expression or activity of a DUX4 polypeptide, or a polypeptide encoded by a downstream target gene of DUX4, in the cell or tissue.
  • the cell or tissue is contacted with an amount of the agent effective to reduce the amount of active p38 protein in the cell or tissue.
  • the cells are muscle cells.
  • the cells are terminally differentiated, e.g., terminally differentiated muscle cells.
  • the cells have an increased expression level of the DUX4 polypeptide, or the polypeptide encoded by the downstream target gene, as compared to the expression level in a control cell (i.e., before treatment).
  • the cells are associated with facioscapulohumeral muscular dystrophy (FSHD), e.g., FSHD 1 or FSHD2.
  • FSHD facioscapulohumeral muscular dystrophy
  • the cells may be derived from or obtained from cells or tissue from a subject diagnosed with FSHD. Methods disclosed herein may be practiced in vitro or in vivo.
  • the disclosure includes a method of treating or preventing a disease or disorder associated with increased activity or expression of a DUX4 protein or a downstream target gene of DUX4 in a subject in need thereof, comprising providing to a subject a pharmaceutical composition comprising an effective amount of an agent that reduces the amount of active p38 protein (e.g., p38-ot and/or ⁇ 38- ⁇ ) in the subject, or in certain cells or tissue of the subject.
  • the agent inhibits the expression or activity of a p38 protein, e.g., p38-ot and/or ⁇ 38- ⁇ .
  • the agent induces degradation of the p38 protein.
  • the agent inhibits activity of a p38 protein, e.g., inhibits kinase activity of the p38 protein.
  • the p38 inhibitor reduces expression of DUX4 and/or one or more DUX4 downstream genes in cells or tissue of the subject.
  • the disease or disorder is selected from FSHD 1, FSHD2, Immunodeficiency, Centromere instability and Facial anomalies syndrome (1CF), amyotrophic lateral sclerosis (ALS), inclusion body myositis (IBM), Ewing's Sarcoma, soft tissue sarcoma, rhabdomyosarcoma, and adult and pediatric B-cell acute lymphoblastic leukemia.
  • the subject is diagnosed with FSHD 1 or FSHD2, and in certain embodiments, the subject comprises one or more genetic mutation associated with FSHD 1 and/or FSHD2. In certain embodiments, the subject comprises reduced repression at a D4Z4 locus. [0074] In certain embodiments of any of the methods disclosed herein, the subject is identified as having FSHD based upon the presence of a transcriptionally active DUX4.
  • the subject is identified as having FSHD based upon the presence of increased expression levels of one or more downstream genes, e.g., ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRX1,
  • downstream genes e.g., ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRX1,
  • the subject is identified as having FSHD based upon the presence of a transcriptionally active DUX4 and increased expression levels of one or more DUX4 downstream genes, e.g., ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A.
  • a transcriptionally active DUX4 and increased expression levels of one or more DUX4 downstream genes e.g., ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A.
  • the method may include measuring the expression level of one or more of DUX4 and DUX4 downstream genes, e.g., DUX4, ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRX1,
  • DUX4 and DUX4 downstream genes e.g., DUX4, ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRX1,
  • the method may further include determining that the subject is in need of treatment if the expression level of one or more of DUX4 and DUX4 downstream genes, e.g., DUX4, ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRX1, PRAMEF20, TRIM49,
  • DUX4 and DUX4 downstream genes e.g., DUX4, ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRX1, PRAMEF20, TRIM49,
  • PRAMEF4 PRAME6, PRAMEF15, and ZNF280A KHDCIL is/are elevated relative to a healthy control.
  • the method may include measuring the expression level of one or more of DUX 4 and DUX4 downstream genes, e.g., DUX4, ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRX1,
  • the method may include comparing the expression level of one or more of DUX4 and DUX4 downstream genes, e.g., DUX4, ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A in the subject before and after the administration of the p38 kinase inhibitor.
  • DUX4 and DUX4 downstream genes e.g., DUX4, ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A in the subject before and after the administration of the p38 kinase inhibitor.
  • the method may include determining the effectiveness of treatment by the comparing of the expression level of one or more of DUX4 and DUX4 downstream genes, e.g., DUX4, ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, and ZNF280A before and after the administration of the p38 kinase inhibitor, wherein a decrease in the expression level(s) is indicative of effective treatment.
  • DUX4 and DUX4 downstream genes e.g., DUX4, ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, and ZNF280A before and after the administration of the
  • the p38 kinase inhibitor reduces one or more downstream genes selected from ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, and ZNF280A.
  • a transcriptional modulator of DUX4 and downstream genes ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, and ZNF280A are inhibited by p38 kinase.
  • the subject comprises contraction of 4q35A D4Z4 array, such that the subject comprises ⁇ 10 or ⁇ 7 repeats (FSHD1).
  • the subject, or one or more cells or tissues of the subject comprises a deletion of one or more macrosatellite D4Z4 repeats in the subtelomeric region of chromosome 4q35, optionally wherein the cell comprises ⁇ 7 macrosatellite D4Z4 repeats in the subtelomeric region of chromosome 4q35.
  • the subject comprises one or more mutations in a Structural Maintenance Of Chromosomes Flexible Hinge Domain Containing 1 (SMCHDl) gene.
  • SMCHDl Structural Maintenance Of Chromosomes Flexible Hinge Domain Containing 1
  • the subject comprises at least one non-deleted 4qA allele. In certain embodiments, the subject comprises at least one non-deleted 4qA allele and an SMCHD l mutation (FSHD2). In some embodiments, the subject is wheelchair bound (e.g., CSS 4.5 and 5). In certain embodiments, during or following treatment, the subject displays a reduced or decreased amount or rate of muscle degeneration e.g., a subject diagnosed with FSHD1 or FSHD2.
  • the subject displays a reduction of skeletal muscle replacement by fat, e.g., as determined via quantitative MRI, e.g., a reduction of at least 5%, at least 10%, at least 20%, at least 30%, at least 50%, or at least 70%.
  • the subject displays evidence of benefit on one or more of the following Clinical Outcome Assessments:
  • the subject displays any of these improvements for at least some time, e.g., for at least one week, one month, two months, six months, or one year following either commencement or cessation of treatment.
  • the disclosure provides the disclosed methods of using p38 inhibitors, e.g., an inhibitor of p38-ot or ⁇ 38- ⁇ , for treatment for FSHD 1, FSHD2, ICF, and diseases where similar pathological changes are found, such ALS and IBM (Tawil et al., 2014).
  • p38 inhibitors e.g., an inhibitor of p38-ot or ⁇ 38- ⁇
  • diseases where similar pathological changes are found, such ALS and IBM (Tawil et al., 2014).
  • the pharmaceutical composition is provided to the subject parenterally.
  • the pharmaceutical composition is provided to a muscle tissue of the subject.
  • any of the methods described herein that comprise providing to the subject a p38 inhibitor may further comprise providing to the subject an additional therapy.
  • the additional therapy comprises clinical management.
  • the present invention provides a method for treating or preventing of FSHD 1, FSHD2, ICF, ALS, IBM, Ewing's Sarcoma, soft tissue sarcoma, rhabdomyosarcoma, and adult and pediatric B-cell acute lymphoblastic leukemia, where p38 inhibitors are used to decrease DUX4 and/or downstream gene and/or protein expression and/or activity and may be combined with clinical management involving physical therapy, aerobic exercise, respiratory function therapy, and/or orthopedic interventions.
  • the additional therapy comprises providing to the subject one or more myostatin inhibitors, anti-inflammatory agents, or gene therapy vectors, e.g., to reduce pathogenic DUX4 protein production in FSHD by controlling D4Z4 methylation, suppressing DUX4 mRNA, and/or inhibiting DUX4 signaling pathways.
  • the present disclosure provides a method of treatment of FSHD 1, FSHD2, ICF, ALS or IBM, in a subject in need thereof, where p38 inhibitors, e.g., inhibitors of p38-ot or ⁇ 38- ⁇ , are used to reduce DUX4 and downstream gene and/or protein expression and may be combined with myostatin inhibitors, anti -inflammatory agents, and/or gene therapy, e.g., to reduce pathogenic DUX4 protein production in FSHD by controlling D4Z4 methylation, suppressing DUX4 mRNA, and inhibiting DUX4 pathways.
  • the methods are practiced using an inhibitor of p38 and a myostatin inhibitor.
  • myostatin pathway inhibitors that act extracellularly by either binding myostatin directly (Fstl3, Follistatin, myostatin antibody, GASP1, myostatin propeptide, decorin peptides, ActRIIB-Fc) or by binding its receptor complex (ActRIIB antibody) in order to block myostatin engaging its receptor complex and activating downstream signaling may be used in certain embodiments.
  • Some of the myostatin inhibitors are naturally occurring (myostatin propeptide, Gaspl, follistatin, Fstl3) whereas others are engineered (myostatin antibody, ActRIIB antibody, ActRIIB-Fc).
  • the additional therapy comprises providing to the subject an inhibitor of DUX4 or a DUX4 downstream target or gene, e.g., an inhibitor that inhibits expression of DUX-4fl mRNA and/or DUX4 protein (or expression of mRNA or protein of a DUX4 downstream target) or an inhibitor that inhibits DUX4 activity, e.g., its activity as a transcriptional activator, or activity of a DUX4 downstream target.
  • an inhibitor of DUX4 or a DUX4 downstream target or gene e.g., an inhibitor that inhibits expression of DUX-4fl mRNA and/or DUX4 protein (or expression of mRNA or protein of a DUX4 downstream target) or an inhibitor that inhibits DUX4 activity, e.g., its activity as a transcriptional activator, or activity of a DUX4 downstream target.
  • the inhibitor induces degradation of DUX4 polypeptide or DUX4 downstream target polypeptide.
  • the inhibitor is an siRNA, miRNA, gRNA, shRNA, or antisense oligonucleotide that specifically binds a nucleic acid sequence or antisense thereof of a DUX4 or a DUX4 downstream target gene.
  • the present invention provides a method of treatment of FSHD 1, FSHD2, ICF, ALS or IBM, where p38 inhibitors are used to reduce DUX4 and downstream gene and protein expression and may be combined with an inhibitor of DUX4 or a DUX4 downstream target, e.g., small interfering RNA (siRNA), small hairpin RNA (shRNA), guide RNA (gRNA), microRNA (miRNA) and antisense oligonucleotides directed at DUX4 and/or one or more DUX4 downstream target transcripts (e.g., DNA or mRNA).
  • siRNA small interfering RNA
  • shRNA small hairpin RNA
  • gRNA guide RNA
  • miRNA microRNA
  • antisense oligonucleotides directed at DUX4 and/or one or more DUX4 downstream target transcripts e.g., DNA or mRNA
  • the present invention provides a method to use small molecule inhibitors of p38 kinase, e.g., an inhibitor of p38-ot or ⁇ 38- ⁇ , to reduce DUX4 and downstream gene expression in FSHD skeletal muscle myotubes to treat FSHD or any other disease or disorder disclosed herein and/or related to aberrant DUX4 expression or activity.
  • small molecule inhibitors of p38 kinase e.g., an inhibitor of p38-ot or ⁇ 38- ⁇
  • p38 e.g., p38-ot and/or ⁇ 38- ⁇
  • p38-ot and/or ⁇ 38- ⁇ is inhibited by any of the small molecules or other agents disclosed herein.
  • p38 inhibitors and/or other agents and compositions (e.g., inhibitors) described herein can be formulated in any manner suitable for a desired administration route (e.g., parenteral or oral administration).
  • contacting an agent or composition with a cell and/or tissue is a result of administration of or providing an agent or composition to a subject.
  • an agent or composition e.g., a p38 inhibitor
  • administration of a first agent or composition is followed by or occurs overlapping with or concurrently with the administration of a second agent or composition.
  • the first and second agent or composition may be the same or they may be different.
  • the first and second agents or compositions are administered by the same actor and/or in the same geographic location. In some embodiments, the first and second agents or compositions are administered by different actors and/or in different geographical locations. In some embodiments, multiple agents described herein are administered as a single composition.
  • p38 inhibitors may be administered or coadministered topically, orally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, intrathecally, transmucosally, pulmonary, or parenterally, for example, by injection, including
  • Subjects includes animals (e.g., mammals, swine, fish, birds, insects etc.).
  • subjects are mammals, particularly primates, especially humans.
  • subjects are livestock such as cattle, sheep, goats, cows, swine, and the like; poultry such as chickens, ducks, geese, turkeys, and the like; and domesticated animals such as dogs and cats.
  • subjects are rodents (e.g., mice, rats, hamsters), rabbits, primates, or swine such as inbred pigs and the like.
  • the terms "subject” and "patient” are used interchangeably herein.
  • tissue is an ensemble of similar cells from the same origin that together carry out a specific function.
  • tissue is muscle tissue.
  • Methods disclosed herein may be practiced with any agent capable of inhibiting expression or activity of a p38 gene or protein, e.g., an inhibitor of a p38-ot or ⁇ 38- ⁇ gene or protein, including but not limited to any of those disclosed herein.
  • methods disclosed herein result in a decrease in an expression level or activity of DUX4 and/or one or more DUX4 downstream genes in cells or tissues (e.g., within a subject), e.g., as compared to the expression level or activity in control cells or tissue not contacted with a p38 inhibitor, or a reference level.
  • “Decrease” refers to a decrease of at least 5%, for example, at least 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99 or 100%, for example, as compared to the reference level.
  • Decrease also means decreases by at least 1-fold, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 500, 1000-fold or more, for example, as compared to the level of a reference or control cells or tissue.
  • Methods described herein may be practiced using any type of inhibitor that results in a reduced amount or level of an active p38 protein, e.g., in a cell or tissue, e.g., a cell or tissue in a subject.
  • the p38 inhibitor causes a reduction in active p38 protein (e.g., active p38-ot and/or ⁇ 38- ⁇ ), a reduction in total p38 protein (e.g., total p38-ot and/or ⁇ 38- ⁇ protein), a reduction in p38 mRNA (e.g., p38-ot and/or ⁇ 38- ⁇ mRNA), and/or a reduction in p38 protein activity (e.g., p38-ot and/or ⁇ 38- ⁇ kinase activity) in a cell or tissue contacted with the p38 inhibitor.
  • active p38 protein e.g., active p38-ot and/or ⁇ 38- ⁇
  • total p38 protein e.g., total p38-ot and/or ⁇ 38- ⁇ protein
  • p38 mRNA e.g., p38-ot and/or ⁇ 38- ⁇ mRNA
  • p38 protein activity e
  • the p38 inhibitor causes a reduction in p38-ot and/or ⁇ 38- ⁇ signaling pathway activity or expression.
  • the reduction is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, as compared to the level in the same type of cell or tissue not contacted with the p38 inhibitor.
  • Methods of measuring total p38 protein or mRNA levels, or p38 kinase activity, in a cell are known in the art.
  • the inhibitor inhibits or reduces p38 activity or expression, e.g., mRNA and/or protein expression.
  • the inhibitor causes increased degradation of the p38 protein, resulting in lower amounts of p38 protein in a cell or tissue.
  • Particular methods may also employ any type of inhibitor of expression or activity of DUX4 or a DUX4 downstream gene.
  • the inhibitor inhibits both p38-ot and p38- ⁇ proteins, while in other instances, the inhibitor selectively or preferentially inhibits either p38-ot or ⁇ 38- ⁇ . In certain embodiments, the inhibitor does not inhibit ⁇ 38- ⁇ .
  • Inhibitors that may be used to practice the disclosed methods include but are not limited to agents that inhibit or reduce or decrease the expression or activity of a biomolecule, (e.g., a protein or nucleic acid), such as but not limited to a p38-ot or ⁇ 38- ⁇ gene, mRNA or protein.
  • a biomolecule e.g., a protein or nucleic acid
  • an inhibitor can cause increased degradation of the biomolecule.
  • an inhibitor can inhibit a biomolecule by competitive, uncompetitive, or non-competitive means.
  • inhibitors include, but are not limited to, nucleic acids, DNA, RNA, gRNA, shRNA, siRNA, modified mRNA (mRNA), microRNA (miRNA), proteins, protein mimetics, peptides, peptidomimetics, antibodies, small molecules, small organic molecules, inorganic molecules, chemicals, analogs that mimic the binding site of an enzyme, receptor, or other protein, e.g., that is involved in signal transduction, therapeutic agents, pharmaceutical compositions, drugs, and combinations of these.
  • the inhibitor can be a nucleic acid molecule including, but not limited to, siRNA that reduce the amount of functional protein in a cell.
  • compounds or agents said to be "capable of inhibiting" a particular protein comprise any type of inhibitor.
  • a p38 inhibitor or an inhibitor of DUX4 or a DUX4 downstream target gene is any of the different classes of inhibitors disclosed herein or any other.
  • a p38 inhibitor (or other inhibitor) comprises a nucleic acid that binds to a p38 gene (e.g., MAPK14 ⁇ gene) or mRNA (or other target gene or mRNA).
  • a nucleic acid inhibitor may comprise a sequence complementary to a target polynucleotide sequence, e.g., the p38-ot sequence disclosed herein, or a region thereof, or an antisense thereof.
  • a nucleic acid inhibitor comprises at least 8, at least 10, at least 12, at least 14, at least 16, at least 20, at least 24, or at least 30 nucleotide sequence corresponding to or complementary to a target polynucleotide sequence or antisense thereof.
  • a nucleic acid inhibitor is an RNA interference or anti-sense RNA agent or a portion or mimetic thereof, or a morpholino, that decreases the expression of a target gene when administered to a cell.
  • a nucleic acid inhibitor comprises at least a portion of a target nucleic acid molecule, or an ortholog thereof, or comprises at least a portion of the complementary strand of a target nucleic acid molecule.
  • expression of a target gene is reduced by 10%, 25%, 50%, 75%, or even 90- 100%.
  • a "complementary" nucleic acid sequence is a nucleic acid sequence capable of hybridizing with another nucleic acid sequence comprised of complementary nucleotide base pairs.
  • hybridize is meant pair to form a double-stranded molecule between
  • adenine (A) forms a base pair with thymine (T), as does guanine (G) with cytosine (C) in DNA
  • T thymine
  • G guanine
  • C cytosine
  • Antisense refers to a nucleic acid sequence, regardless of length, that is complementary to a nucleic acid sequence.
  • antisense RNA refers to single stranded RNA molecules that can be introduced to an individual cell, tissue, or subject and results in decreased expression of a target gene through mechanisms that do not rely on endogenous gene silencing pathways.
  • An antisense nucleic acid can contain a modified backbone, for example, phosphorothioate, phosphorodithioate, or others known in the art, or may contain non-natural intemucleoside linkages.
  • Antisense nucleic acid can comprise, e.g., locked nucleic acids (LNA).
  • RNA interference refers to the use of agents that decrease the expression of a target gene by degradation of a target mRNA through endogenous gene silencing pathways (e.g., Dicer and RNA-induced silencing complex (RISC)). RNA interference may be accomplished using various agents, including shRNA and siRNA.
  • shRNA short hair-pin RNA
  • shRNA refers to a double stranded, artificial RNA molecule with a hairpin turn that can be used to silence target gene expression via RNA interference (RNAi).
  • RNAi RNA interference
  • Expression of shRNA in cells is typically accomplished by delivery of plasmids or through viral or bacterial vectors.
  • shRNA is an advantageous mediator of RNAi in that it has a relatively low rate of degradation and turnover.
  • siRNA Small interfering RNA
  • RNAi RNA interference pathway
  • an siRNA is 18, 19, 20, 21, 22, 23 or 24 nucleotides in length and has a 2 base overhang at its 3' end.
  • siRNAs can be introduced to an individual cell and/or culture system and result in the degradation of target mRNA sequences.
  • Morpholino refers to a modified nucleic acid oligomer wherein standard nucleic acid bases are bound to morpholine rings and are linked through phosphorodiamidate linkages. Similar to siRNA and shRNA, morpholinos bind to complementary mRNA sequences. However, morpholinos function through steric-inhibition of mRNA translation and alteration of mRNA splicing rather than targeting complementary mRNA sequences for degradation.
  • a nucleic acid inhibitor is a messenger RNA that may be introduced into a cell, wherein it encodes a polypeptide inhibitor of p38 or other target disclosed herein.
  • the mRNA is modified, e.g., to increase its stability or reduce its immunogenicity, e.g., by the incorporation of one or more modified nucleosides. Suitable modifications are known in the art.
  • an inhibitor comprises an expression cassette that encodes a polynucleotide or polypeptide inhibitor of p38 or other target disclosed herein.
  • the expression cassette is present in a gene therapy vector, for example a viral gene therapy vector.
  • a variety of gene therapy vectors, including viral gene therapy vectors are known in the art, including, for example, AAV-based gene therapy vectors.
  • an inhibitor is a polypeptide inhibitor.
  • a polypeptide inhibitor binds to a target polypeptide such as p38, thus inhibiting its activity, e.g., kinase activity.
  • polypeptide inhibitors include any types of polypeptides (e.g., peptides and proteins), such as antibodies and fragments thereof.
  • an “antibody” is an immunoglobulin (Ig) molecule capable of specific binding to a target, such as a carbohydrate, polynucleotide, lipid, or polypeptide, through at least one epitope recognition site, located in the variable region of the Ig molecule.
  • a target such as a carbohydrate, polynucleotide, lipid, or polypeptide
  • the term encompasses not only intact polyclonal or monoclonal antibodies, but also fragments thereof, such as dAb, Fab, Fab', F(ab')2, Fv, single chain (scFv), synthetic variants thereof, naturally occurring variants, fusion proteins comprising an antibody portion with an antigen- binding fragment of the required specificity, chimeric antibodies, nanobodies, and any other modified configuration of the immunoglobulin molecule that comprises an antigen-binding site or fragment of the required specificity.
  • “Fragment” refers to a portion of a polypeptide or nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide.
  • a fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.
  • a “functional fragment” of an antibody is a fragment that maintains one or more activities of the antibody, e.g., it binds the same epitope and or possesses a biological activity of the antibody. In particular embodiments, a functional fragment comprises the six CDRs present in the antibody.
  • the inhibitor induces degradation of a target polypeptide, e.g., p38 protein.
  • inhibitors include proteolysis targeting chimeras (PROTAC), which induce selective intracellular proteolysis of target proteins.
  • PROTACs include functional domains, which may be covalently linked protein-binding molecules: one is capable of engaging an E3 ubiquitin ligase, and the other binds to the target protein meant for degradation. Recruitment of the E3 ligase to the target protein results in ubiquitination and subsequent degradation of the target protein by the proteasome.
  • an inhibitor is a PROTAC that targets a p38 protein (e.g., p38-ot and/or ⁇ 38- ⁇ ).
  • an inhibitor is a small molecule inhibitor, or a stereoisomer, enantiomer, diastereomer, isotopically-enriched, pro-drug, or pharmaceutically acceptable salt thereof.
  • the p38 inhibitor inhibits p38-ot and/or ⁇ 38- ⁇ . In particular embodiments, it does not significantly inhibit ⁇ 38- ⁇ .
  • a small molecule inhibitor of p38 includes but is not limited to any of the small molecule compounds disclosed herein, including but not limited to those shown in FIG. 12B. A variety of p38 inhibitors are known and available, and some are in clinical development. Any of these may be used.
  • inhibitor compounds include, but are not limited to:
  • Certain inhibitor compounds of the present invention may exist in stereoisomeric forms (e.g., they may contain one or more asymmetric carbon atoms or may exhibit cis-trans isomerism). Some compounds may include more than one asymmetric carbon atoms.
  • Stereoisomer refers to a compound that differ in orientation (R/S) about one or more asymmetric carbon atom(s), or differs in orientation (cis:trans) about a double bond.
  • the term stereoisomer may also encompass atropisomers, which arise from hindered rotation about a single bond, e.g., in compounds having a substituted biphenyl moiety.
  • enantiomer is a compound that is a mirror image of another compound, i.e., all asymmetric carbon atoms of an enantiomer exist in opposite orientation (R/S) with respect to the other compound.
  • a "diastereomer” is a compound that is not a mirror image of another compound, but includes one or more asymmetric carbon atoms existing in opposite orientation (R/S) with respect to the other compound.
  • the embodiments of the present invention may include mixtures of stereoisomers, or may include a single stereoisomer. Single enantiomers or diastereomers may be prepared beginning with chiral reagents or by stereoselective or stereospecific synthetic techniques.
  • the single enantiomers or diastereomers may be isolated from mixtures by standard chiral chromatographic or crystallization techniques.
  • “Isotopically-enriched” refers to a compound wherein one or more atoms is enriched with an isotope beyond its natural abundance. For example, the natural abundance of deuterium is 0.015%.
  • An isoptically-enriched compound may have one or more specific chemical sites wherein the H/D ratio is greater than 0.015%.
  • An isotopically-enriched compound may be refered to as isotopically-labeled.
  • the inhibitor comprises one or more components of a gene editing system.
  • a gene editing system refers to a protein, nucleic acid, or combination thereof that is capable of modifying a target locus of an endogenous DNA sequence when introduced into a cell.
  • Numerous gene editing systems suitable for use in the methods of the present invention are known in the art including, but not limited to, zinc-finger nuclease systems, TALEN systems, and CRISPR/Cas systems.
  • the gene editing system used in the methods described herein is a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas (CRISPR Associated) nuclease system, which is an engineered nuclease system based on a bacterial system that can be used for mammalian genome engineering.
  • the system comprises a CRISPR-associated endonuclease (for example, a Cas endonuclease) and a guide RNA (gRNA).
  • the gRNA is comprised of two parts; a crispr-RNA (crRNA) that is specific for a target genomic DNA sequence, and a trans-activating RNA (tracrRNA) that facilitates endonuclease binding to the DNA at the targeted insertion site.
  • crRNA crispr-RNA
  • tracrRNA trans-activating RNA
  • the crRNA and tracrRNA may be present in the same RNA oligonucleotide, referred to as a single guide-RNA (sgRNA).
  • the crRNA and tracrRNA may be present as separate RNA oligonucleotides.
  • the gRNA is comprised of a crRNA oligonucleotide and a tracrRNA oligonucleotide that associate to form a crRNA :tracrRNA duplex.
  • guide RNA or "gRNA” refers to the combination of a tracrRNA and a crRNA, present as either an sgRNA or a crRNA:tracrRNA duplex.
  • the CRISPR/Cas systems comprise a Cas protein, a crRNA, and a tracrRNA.
  • the crRNA and tracrRNA are combined as a duplex RNA molecule to form a gRNA.
  • the crRNA :tracrRNA duplex is formed in vitro prior to introduction to a cell.
  • the crRNA and tracrRNA are introduced into a cell as separate RNA molecules and crRNA:tracrRNA duplex is then formed intracellularly.
  • polynucleotides encoding the crRNA and tracrRNA are provided.
  • the polynucleotides encoding the crRNA and tracrRNA are introduced into a cell and the crRNA and tracrRNA molecules are then transcribed intracellularly.
  • the crRNA and tracrRNA are encoded by a single polynucleotides.
  • the crRNA and tracrRNA are encoded by separate polynucleotides.
  • a Cas endonuclease is directed to the target insertion site by the sequence specificity of the crRNA portion of the gRNA, which may include a protospacer motif (PAM) sequence near the target insertion site.
  • PAM protospacer motif
  • a variety of PAM sequences suitable for use with a particular endonuclease are known in the art (See e.g. , Nat Methods. 2013 Nov; 10( 11): 1 116-1 121 and Sci Rep. 2014; 4: 5405).
  • the specificity of a gRNA for a target locus is mediated by the crRNA sequence, which comprises a sequence of about 20 nucleotides that are complementary to the DNA sequence at a target locus, e.g., complementary to a p38-ot or p-38- ⁇ DNA sequence.
  • the crR A sequences used in the methods of the present invention are at least 90% complementary to a DNA sequence of a target locus.
  • the crRNA sequences used in the methods of the present invention are at least 95%, 96%, 97%, 98%, or 99% complementary to a DNA sequence of a target locus.
  • the crRNA sequences used in the methods of the present invention are 100% complementary to a DNA sequence of a target locus, e.g., 3.MAPK14 oxMAPKll gene.
  • the crRNA sequences described herein are designed to minimize off-target binding using algorithms known in the art (e.g., Cas-OFF finder) to identify target sequences that are unique to a particular target locus or target gene.
  • the endonuclease is a Cas protein or ortholog. In some embodiments, the endonuclease is a Cas9 protein. In some embodiments, the Cas9 protein is derived from Streptococcus pyogenes (e.g., SpCas9), Staphylococcus aureus (e.g. , SaCas9), or Neisseria meningitides (NmeCas9).
  • Streptococcus pyogenes e.g., SpCas9
  • Staphylococcus aureus e.g. , SaCas9
  • Neisseria meningitides Neisseria meningitides
  • the Cas endonuclease is a Cas9 protein or a Cas9 ortholog and is selected from the group consisting of SpCas9, SpCas9-HFl, SpCas9-HF2, SpCas9-HF3, SpCas9-HF4, SaCas9, FnCpf, FnCas9, eSpCas9, and NmeCas9.
  • the endonuclease is selected from the group consisting of C2C1, C2C3, Cpfl (also referred to as Casl2a), Casl, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csxl2), CaslO, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, and Csf4.
  • the endonuclease
  • compositions e.g., pharmaceutical compositions comprising an inhibitor of p38, including any of the various classes of inhibitors described herein.
  • the invention encompasses pharmaceutical compositions comprising a p38 inhibitor and a pharmaceutically acceptable carrier, diluent or excipient. Any inert excipient that is commonly used as a carrier or diluent may be used in compositions of the present invention, such as sugars, polyalcohols, soluble polymers, salts and lipids. Sugars and polyalcohols which may be employed include, without limitation, lactose, sucrose, mannitol, and sorbitol.
  • soluble polymers which may be employed are polyoxyethylene, poloxamers, polyvinylpyrrolidone, and dextran.
  • Useful salts include, without limitation, sodium chloride, magnesium chloride, and calcium chloride.
  • Lipids which may be employed include, without limitation, fatty acids, glycerol fatty acid esters, glycolipids, and phospholipids.
  • compositions may further comprise binders (e.g., acacia, cornstarch, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone), disintegrating agents (e.g., cornstarch, potato starch, alginic acid, silicon dioxide, croscarmellose sodium, crospovidone, guar gum, sodium starch glycolate, Primogel), buffers (e.g., tris-HCL, acetate, phosphate) of various pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), protease inhibitors, surfactants (e.g., sodium lauryl sulfate), permeation enhancers, solubilizing agents (e.g., glycerol), e.glycerol
  • the pharmaceutical compositions are prepared with carriers that will protect the p38 inhibitor against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
  • Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
  • the invention encompasses pharmaceutical compositions comprising any solid or liquid physical form of a p38 inhibitor.
  • the p38 inhibitor can be in a crystalline form, in amorphous form, and have any particle size.
  • the particles may be micronized, or may be agglomerated, particulate granules, powders, oils, oily suspensions or any other form of solid or liquid physical form.
  • solubilizing the compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, pH adjustment and salt formation, using co-solvents, such as ethanol, propylene glycol, polyethylene glycol (PEG) 300, PEG 400, DMA (10-30%), DMSO (10- 20%), NMP (10-20%), using surfactants, such as polysorbate 80, polysorbate 20 (1-10% ), cremophor EL, Cremophor RH40, Cremophor RH60 (5-10% ), Pluronic F68/Poloxamer 188 (20-50%), Solutol HS 15 (20-50%), Vitamin E TPGS, and d-a-tocopheryl PEG 1000 succinate (20-50%), using complexation such as HP ⁇ -CD and SBE ⁇ -CD (10-40%), and using advanced approaches such as micelles, addition of a polymer, nanoparticle suspensions, and liposome
  • p38 inhibitors may also be administered or coadministered in slow release dosage forms.
  • p38 inhibitors may be in gaseous, liquid, semi-liquid or solid form, formulated in a manner suitable for the route of administration to be used.
  • suitable solid oral formulations include tablets, capsules, pills, granules, pellets, sachets and effervescent, powders, and the like.
  • suitable liquid oral formulations include solutions, suspensions, dispersions, syrups, emulsions, oils and the like.
  • reconstitution of a lyophilized powder is typically used.
  • Suitable doses of the p38 inhibitors for use in treating the diseases or disorders described herein can be determined by those skilled in the relevant art. Therapeutic doses are generally identified through a dose ranging study in humans based on preliminary evidence derived from the animal studies. Doses should be sufficient to result in a desired therapeutic benefit without causing unwanted side effects. Mode of administration, dosage forms and suitable pharmaceutical excipients can also be well used and adjusted by those skilled in the art. All changes and modifications are envisioned within the scope of the present patent application.
  • the disclosure includes unit dosage forms of a pharmaceutical composition comprising an agent that inhibits expression or activity of a p38 polypeptide (or results in reduced levels of an active p38 protein) and a pharmaceutically acceptable carrier, diluent or excipient, wherein the unit dosage form is effective to reduce expression of a DUX4 polypeptide, or a polypeptide encoded by a downstream target gene of DUX4, in one or more tissue in a subject to whom the unit dosage form is administered.
  • the downstream target gene is MBD3L2, ZSCAN4, LEUTX, PRAMEF2, TRIM43, or KHDC1L.
  • the downstream target gene is RFPL2, CCNA1, SLC34A2, TPRX1, KHDC1L, ZSCAN4, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF 15 or ZNF280A.
  • the tissue is muscle tissue.
  • the tissue is terminally differentiated, e.g., terminally differentiated muscle tissue.
  • the tissue comprises cells comprising a mutation associated with facioscapulohumeral muscular dystrophy (FSHD).
  • FSHD facioscapulohumeral muscular dystrophy
  • the agent binds a p38 polypeptide (e.g., p38-ot or ⁇ 38- ⁇ ) or binds a polynucleotide encoding the p38 polypeptide.
  • the agent comprises or consists of: a nucleic acid, optionally a DNA, R A, modified mR A (mmR A), shRNA, siR A, guide RNA (gRNA), microRNA (miRNA) or antisense oligonucleotide.
  • the agent comprises or consists of: a polypeptide, optionally a protein, a peptide, a protein mimetic, a peptidomimetic, or an antibody or functional fragment thereof.
  • the agent comprises: a small molecule, optionally an organic molecule or an inorganic molecule.
  • the agent comprises a gene expression cassette, optionally a gene therapy vector, that expression a polynucleotide or polypeptide agent that inhibits expression or activity of a p38 polypeptide.
  • the unit dosage forms comprise an effective amount, an effective concentration, and/or an inhibitory concentration, of a p38 inhibitor to treat a disease or disorder associated with increased activity or expression of DUX4 and/or a downstream DUX4 target gene, including any of the disease or disorders disclosed herein, e.g., FSHD.
  • compositions include compositions of one or more agents capable of is capable of being administered or delivered to a subject and/or cell for the prevention and/or treatment of a particular disease or disorder.
  • “Pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • “Pharmaceutically acceptable carrier” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, surfactant, and/or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans and/or domestic animals.
  • Exemplary pharmaceutically acceptable carriers include, but are not limited to, to sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; tragacanth; malt; gelatin; talc; cocoa butter, waxes, animal and vegetable fats, paraffins, silicones, bentonites, silicic acid, zinc oxide; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen- free water
  • Ringer's solution ethyl alcohol; phosphate buffer solutions; and any other compatible substances employed in pharmaceutical formulations. Except insofar as any conventional media and/or agent is incompatible with the agents of the present disclosure, its use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.
  • Effective amount refers to an amount of an agent effective in achieving a particular effect, e.g., reducing DUX4-fl mRNA or DUX4 protein, or mRNA or protein of one or more DUX4 downstream targets in a cell, tissue, organ or subject.
  • an effective amount may be, e.g., an amount effective or sufficient to reduce one or more disease symptoms in the subject, e.g., a subject with FSHD.
  • the reduction is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70%, as compared to the amount prior to or without treatment.
  • Effective Concentration refers to the minimum concentration (mass/volume) of an agent and/or composition required to result in a particular physiological effect. As used herein, effective concentration typically refers to the concentration of an agent required to increase, activate, and/or enhance a particular physiological effect.
  • inhibitory Concentration is the minimum concentration (mass/volume) of an agent required to inhibit a particular physiological effect. As used herein, inhibitory concentration typically refers to the concentration of an agent required to decrease, inhibit, and/or repress a particular physiological effect.
  • an agent or compound described herein may be administered at a dosage from about 1 mg/kg to about 300 mg/kg. In another embodiment, an agent or compound described herein may be administered at a dosage from about 1 mg/kg to about 20 mg/kg. For example, the agent or compound may be administered to a subject at a dosage of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19 or 20 mg/kg, or within a range between any of the proceeding values, for example, between about 10 mg/kg and about 15 mg/kg, between about 6 mg/kg and about 12 mg/kg, and the like. In another embodiment, an agent or compound described herein is administered at a dosage of ⁇ 15 mg/kg.
  • an agent or compound may be administered at 15 mg/kg per day for 7 days for a total of 105 mg/kg per week.
  • a compound may be administered at 10 mg/kg twice per day for 7 days for a total of 140 mg/kg per week.
  • the dosages described herein may refer to a single dosage, a daily dosage, or a weekly dosage.
  • an agent or compound may be administered once per day.
  • a compound may be administered twice per day.
  • an agent or compound may be administered three times per day.
  • a compound may be four times per day.
  • an agent or compound described herein may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 times per week.
  • the compound is administered once biweekly.
  • an agent or compound described herein may be administered orally. In some embodiments, an agent or compound described herein may be administered orally at a dosage of ⁇ 15 mg/kg once per day.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
  • the dosage regimen utilizing the disclosed compound is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the patient; and the particular disclosed compound employed.
  • a physician or veterinarian of ordinary skill in the art can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • the present invention relates to methods used for screening to identify drug targets using small molecules and/or genomic tools (e.g., small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA), antisense oligonucleotides and gene therapeutic viruses) that reduce the expression and/or activity of DUX4 and downstream transcripts, MBD3L2, in FSHD myotubes.
  • small molecules and/or genomic tools e.g., small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA), antisense oligonucleotides and gene therapeutic viruses
  • the methods comprise contacting a myotube comprising FSHD cells, for example, cells comprising an FSHD 1 and/or an FSHD2 defect (e.g., mutation) with one or more candidate agent, and then determining whether myotubes contacted with the candidate agent have reduced DUX4 activity, reduced levels of DUX4 mRNA or protein, reduced activity of one or more downstream genes regulated by DUX4; or reduced levels of one or more downstream genes regulated by DUX4, as compared to the levels in myotubes contacted with a negative control, e.g., vehicle only.
  • a negative control e.g., vehicle only.
  • Candidate agents associated with reduced activity or expression levels of DUX4 and/or a DUX4 downstream gene are then identified, and the targets that they modulate may be identified.
  • the gene target of the siRNA associated with reduced expression of DUX4 and/or a DUX4 downstream target gene is identified as a drug target for treating diseases or disorders associated with aberrant expression of DUX4 and/or a downstream DUX4 target gene, including any of those described herein, e.g., FSHD.
  • the drug target of the small molecule associated with reduced activity or expression of DUX4 and/or a DUX4 downstream target gene is identified as a drug target for treating diseases or disorders associated with aberrant expression of DUX4 and/or a downstream DUX4 target gene, including any of those described herein, e.g., FSHD.
  • the methods may be practiced by assessing a physical or qualitative property of the myotubes, in order to identify a candidate agent and its target, which may be used to improve the physical or qualitative property of the myotubes, thus identifying the target as a therapeutic target for treating diseases or disorders associated with aberrant expression of DUX4 and/or a downstream DUX4 target gene, including any of those described herein, e.g., FSHD.
  • the disclosure includes a method of identifying an agent that inhibits expression of a DUX4 protein, or inhibits expression of a protein encoded by a downstream gene target of DUX4, the method comprising: contacting a myotube prepared from cells associated with facioscapulohumeral muscular dystrophy (FSHD) with a candidate agent; and determining an expression level of the DUX4 protein, a polynucleotide encoding the DUX4 protein, the downstream gene target of DUX4, or a polynucleotide encoding the downstream gene target of DUX4 in the myotube, wherein the candidate agent is identified as an agent that inhibits expression of the DUX4 protein, or the protein encoded by the downstream gene target, if the expression level determined after the contacting is reduced as compared to the expression level of the DUX4 protein or the protein encoded by the downstream gene target in a myotube prepared from cells associated with FSHD not contacted with the candidate agent or
  • FSHD facios
  • the candidate agent may be any of the classes of inhibitors disclosed herein, including small molecules, polypeptides, and nucleic acids, such as, e.g., wherein the candidate agent comprises or consists of: a nucleic acid, optionally a DNA, RNA, gR A, shR A, miRNA, siRNA, or antisense oligonucleotide; a polypeptide, optionally a protein, a peptide, a protein mimetic, a peptidomimetic, gene therapy vector, or an antibody or functional fragment thereof; or a small molecule, optionally an organic molecule or an inorganic molecule.
  • a nucleic acid optionally a DNA, RNA, gR A, shR A, miRNA, siRNA, or antisense oligonucleotide
  • a polypeptide optionally a protein, a peptide, a protein mimetic, a peptidomimetic, gene therapy vector, or an antibody or functional fragment thereof
  • the downstream target gene is, for example, MBD3L2, ZSCAN4, LEUTX, PRAMEF2, TRIM43, or KHDCIL.
  • the downstream target gene is, for example, ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDCIL, RFPL2, CCNAl, SLC34A2, TPRXl, PRAMEF20, TRIM49, PRAMEF4, PRAME6, or PRAMEF15.
  • any of the methods described herein are performed by screening a library of potential candidate agents. In certain embodiments, the methods are performed using high throughput assays.
  • the methods are performed using mature patient derived FSHD myotubes.
  • a library of small molecules are used to screen for target modifiers of DUX4 or downstream target genes expression or activity in FSHD myotubes.
  • Three days prior to treatment cells are plated at 15,000 cells per well in a gelatinized 96 well plate with skeletal muscle growth medium (PromoCell, C-23060) with 20% FBS and Pen/Strep (Gibco, 15140148).
  • the media is changed to Skeletal Muscle Cell Differentiation Medium (PromoCell, C-23061) supplemented with 20%
  • KnockOut Serum replacement (Gibco, 10828010) or NbActiv4 medium (BrainBits Nb4-500) and Pen/Strep.
  • p38 modulating agents are added at desired concentration into the culture media containing differentiated FSHD myotubes and cultured for 3-4 days in incubator. Myotubes are removed from incubator and RNA is extracted using RNeasy Micro Plus Kit (Qiagen Cat No./ID:74034).
  • cDNA is prepared from the extracted RNA for Taqman Gene Expression assay to measure DUX4 or downstream target genes expression.
  • POL2RA transcript is used as endogenous control.
  • MYOG myogenin (myogenic factor 4)
  • FTCE-00016-01 immortalized FSDH myoblast line, 6.3 repeats
  • isogenic lines A4 control healthy normal
  • C12 FSHD myoblasts were used for all studies (as described in Mamchaoui et al., 2011; Thorley et al., 2016).
  • Four distinct primary patient myoblast lines, FTCE-016, -020, -197, -196 were provided by R. Tawil.
  • the FSHD myoblasts were shown to express aberrant DUX4 via demethylation of the D4Z4 on chromosome 4q35.
  • Media components and tissue culture materials included:
  • ASOs Antisense oligonucleotides
  • ASOs were purchased from Exiqon: FTSE-000001 (DUX4 ASO from Exiqon, CAGCGTCGGAAGGTGG (SEQ ID NO: 18), 300610)), and non-targeting ASO (Exiqon, AACACGTCTATACGC (SEQ ID NO: 19, 300610).
  • 0.1% gelatin solution was made by combining 1 g gelatin (e.g. Sigma G9391) and 1 L tissue culture grade water; autoclaved for 30 minutes to dissolve, and sterilized. Sufficient 0.1% gelatin to coat dish was applied using a sterile pipette, then the solution was aspirated, and the dishes were air-dried and stored at room temperature.
  • 1 g gelatin e.g. Sigma G9391
  • 1 L tissue culture grade water e.g. Sigma G9391
  • Sufficient 0.1% gelatin to coat dish was applied using a sterile pipette, then the solution was aspirated, and the dishes were air-dried and stored at room temperature.
  • Antisense oligonucleotide and compound treatment
  • Skeletal muscle myotube differentiation [0153] On day 0, the media was changed to differentiation media. Plates were removed from the incubator and the growth medium was aspirated, plates were washed once with PBS, 100 for 96-wells and 1 mL for a 6-well plate, 100 or 2 mL of differentiation medium was added per well, 96- or 6-well respectively. Antisense oligonucleotides or drug were added at the desired concentration, and the plates were put back in the incubator and incubated for 3-4 days.
  • RNA (1 : 10 dilution lysate) was diluted 1 : 10, and 2 ⁇ was used for a 10 ⁇ 1 -step RT- qPCR reaction for detection of GAPDH, RPLP0, TBP, MYOG, FRG1, MYH3, ACTN2, etc..
  • the reaction mix included: 2 ⁇ of RNA (1 : 10 dilution lysate), 5 ⁇ of Fast Advanced Taqman Master Mix (2X), 0.25 ⁇ ⁇ of RT enzyme mix (40X), 0.5 ⁇ ⁇ of Taqman probe set (20X), and 2.25 ⁇ of H2O.
  • RT-Preamplification was used for detection of DUX4 downstream genes, i.e., ,MBD3L2, ZSCAN4, LEUTX, TRIM43, KHDC1L, and POL2RA-VIC was used as endogenous control.
  • the reaction mix included: 2.25 ⁇ of RNA (1 : 10 dilution lysate), 5 ⁇ ⁇ of Taqman Pre-Amp Master Mix (2X), 0.25 ⁇ ⁇ of RT enzyme mix (40X), 2.5 ⁇ ⁇ of Taqman probe set (0.2X)* .
  • each 20X TaqMan® Gene Expression Assay was used, and up to 100 assays were combined.
  • 10 ⁇ ⁇ of each assay were combined in a microcentrifuge tube.
  • the pooled TaqMan assays were diluted using IX TE buffer so that each assay was at a final concentration of 0.2X.
  • 500 ⁇ ⁇ of IX TE buffer was added to the pooled TaqMan assays for a total final volume of 1 mL.
  • the QuantStudio7 protocol was used at 48 °C 15 min, 95 °C 10 min, 10 cycles: 95 °C 15 sec, 60 °C 4 min, and 4 °C infinite. Samples were then diluted to 50 and continued with the qPCR step. Per ⁇ 0 ⁇ ⁇ reaction, the reaction mix included: 2 of Preamp dilution, 5 of Fast Advanced Taqman Master Mix (2X), 0.5 of Taqman probe set (20X), and 2.5 ⁇ of H2O. When multiplexing, the volume was adjusted to 10 ⁇ total.
  • Buffer RWl per manufactures specification
  • 500 ⁇ ⁇ Buffer RPE was added to the RNeasy MinElute spin column, which was then centrifuged for 15 s at >8000 x g, after which the flow-through was discarded.
  • 500 ⁇ ⁇ of 80% ethanol was added to the RNeasy MinElute spin column, the column was centrifuged for 2 min at >8000 x g to wash the spin column membrane, and the collection tube was discarded with the flow-through.
  • the RNeasy MinElute spin column was placed in a new 2 mL collection tube (supplied), centrifuged at full speed for 5 min to dry the membrane, and the collection tube was discarded with the flow through.
  • the RNeasy MinElute spin column was placed in a new 1.5 mL collection tube (supplied). 14 ⁇ ⁇ of RNase-free water was added directly to the center of the spin column membrane, which was then centrifuged for 1 min at full speed to elute the RNA. Approximately 12 ⁇ ⁇ of RNA was eluted.
  • RNA samples included 1 of RNA (1 ⁇ g), 0.5 of Oligo dT, 0.5 ⁇ ⁇ of 10 mM dNTPs, and 4.5 ⁇ ⁇ of H2O. Reaction samples were incubated at 65 °C for 2 min and quickly moved to ice and held at least 1 min before adding the enzyme mix, which included 2 ⁇ , of 5x First strand Buffer, 0.5 ⁇ , of 0.1M DTT, 0.5 ⁇ , of RNAse inhibitor, 0.5 ⁇ of SSIV RT.
  • DUX4 pre -amplification was performed in a 10 ⁇ reaction mixture containing 1 ⁇ of RT reaction, 2 ⁇ of 5X GC buffer, 0.8 ⁇ of DMSO, 0.2 ⁇ . of 10 mM dNTPs, 0.2 ⁇ , of 10 ⁇ TJ38F, 0.2 ⁇ _ ⁇ of 10 ⁇ TJ40R, 0.1 ⁇ . of Phusion II DNA pol, and 5.5 ⁇ of H2O.
  • the following protocol was run on the QuantStudio 7: 98 °C 2 min, 10 cycles of 98 °C 15 seconds, 64 °C 20 seconds, 72 °C 15 seconds, and 4 °C infinite.
  • DUX4 qPCR with nested primers was performed in a 10 ⁇ reaction containing 1 ⁇ of DUX4 pre amplification DNA, 5 ⁇ . of 2X IQ SYBR Mix, 0.4 ⁇ , of 10 ⁇ TJ38F, 0.4 ⁇ . of 10 ⁇ TJ41R, and 3.2 ⁇ FhO.
  • the following protocol was run on the QuantStudio7: 95 °C 3 min, 40 cycles of 95 °C 10 seconds, 64 °C 15 seconds, 72 °C 20 seconds, 86 °C 10 seconds, then the plates were read on QuantStudio7 as per manufactures instruction
  • the 40 bp single-end reads from Illumina had good quality by checking with FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).
  • Reads were mapped to hgl9 using TopHat v2.1.1.
  • the gene model for TopHat was created by merging knownGene in gtf format with kgXref table. Both known gene and kgXref were downloaded from UCSC table browser in hgl9 assembly.
  • the read counts were obtained using feature Counts function from Subread package with strandness option as -r 2.
  • Reads were normalized with DESeq2.
  • crRNAs were purchased from Thermo Fisher Scientific and annealing to tracrRNAs was performed according to specifications. In short, crRNAs and tracrRNA were resuspended in TE buffer at 100 ⁇ , mixed, and diluted 5 -fold in annealing buffer.
  • polyadenylation sequence of DUX4, 4 gRNAs were: NT-CTRL,
  • GCTGAACAAGACAATCTGGG (SEQ ID NO:9), CTGCTTTTGACACAAAAACG (SEQ ID NO: 10), CTTATCTACCAAATTCTCCG (SEQ ID NO: 11); pLAM, AGAATTTCACGGAAGAACAA (SEQ ID NO: 12), CAGGTTTGCCTAGACAGCGT (SEQ ID NO: 13), ATTAAAATGCCCCCTCCCTG (SEQ ID NO: 14),
  • AATCTTCTATAGGATCCACA SEQ ID NO: 15
  • siRNA MAPK14 siRNA MAPK14
  • the diet (Certified Rodent Diet #5002, PMI Feeds, Inc., Brentwood, MO) was irradiated pellets with double package; diet lot number and specifications will be recorded in study notebook and archived at WuXi AppTec. Water (reverse osmosis) was provided to the animals ad libitum. Periodic analyses of water quality were performed, and the results were archived at WuXi AppTec. There are no known contaminants in the diet or water that, at the levels of detection, is expected to interfere with the outcome of the study. In study # FULTH- 20171120 rats were fasted overnight prior to drug administration: rats were allowed free access to water at all times and were fed 4 hours post dosing. For study # FULTH-20171228 rats were allowed ad-libitum access to food and water throughout the study.
  • mice Male NOD.Cg-RagltmlMom I12rgtmlWjl/SzJ (Nod-Rag) mice (6-8 weeks of age) were supplied by the University of Maryland VR breeding colony (USA). Animals were housed in the UMB central animal facility at Howard Hall at the University of Maryland. Animals were group housed (4/cage) during acclimation (4-5 days), throughout the engraftment procedure and throughout the drug treatment study. The animal room environment was controlled according to facility operation (target conditions: temperature 20 to 26°C, relative humidity 30 to 70%, 12-hour cycle of lights on and off). Lights, temperature and relative humidity are constantly monitored by AmegaView Environmental Monitoring System.
  • the diet (LabDiets 5P76 22.5% protein rodent chow) was provided ad libitum during the study. Sterilized water was provided ad libitum. There are no known contaminants in the diet or water that were expected to interfere with the outcome of the study.
  • FSHD and control mice were generated by xenografting C6 and A4 IPSC-derived human immortalized isogeneic myoblast cell lines into the bilateral tibialis anterior (TA) muscles of approximately 8-week old male Nod-Rag mice.
  • TA bilateral tibialis anterior
  • a niche to seed the A4 or C6 cells within the TA of the mouse hindlimb was created by X-irradiating the hindlimbs of the 8-week-old immunodeficient NRG mice, to prevent mouse muscle regeneration.
  • 50 ul of a 2% BaC12 solution was injected along the length of each TA to eliminate the mouse muscle tissue.
  • 2x106 C6 cells were injected into each, bilateral, TA region and allowed to develop for four weeks. Following engraftment of the A4 or C6 cells, the animals were exposed to 4 weeks of intermittent neuromuscular electrical stimulation (iNMES) in order to improve the engraftment of the human cells as described by Sakellariou et al, 2016.
  • iNMES intermittent neuromuscular electrical stimulation
  • FTX-1821 were accurately weighed and mixed with appropriate volume of excipients (0.5% (1% DMSO:99% methyl cellulose) in water to get a uniform suspension with a final concentration of 0.03 mg/mL. Formulation was prepared on the day of the study and was dosed within 1 hour of preparation. Dose volume given to animals was lOmL/kg. Two 20-50 aliquots of dose solution were taken from each formulation and set aside for the determination of dose accuracy by LC-MS/MS.
  • the dosing solution of FTX-1821 (0.03mg/mL) was administered via oral gavage at a dose volume of 10 mL/kg in order to yield a final dose of 0.3 mg/kg. following Wuxi facility SOPs. Dose volume was determined by measured body weight prior to dosing. The dosing solution concentrations (mg/ML), dose volumes (mL/kg) and final dose (mg/kg) for the respective treatment groups were recorded in the included excel study sheet. Feeding condition: overnight fast, food return 4 hours after dosing.
  • FTX-2865 Test Article Administration and Xenograft Study Design [0171] The dosing solution of FTX-2865 (lmg/mL) was administered via IP injection at a dose volume of 10 mL/kg in order to yield a final dose of 10 mg/kg (for each dose). 0.9% sterile saline was administered via IP injection at a dose volume of 10 mL/kg as a vehicle control (for each dose). Dose volume was determined by measured body weight prior to the morning dosing. The dosing solution concentrations (mg/ML), dose volumes (mL/kg) and final dose (mg/kg) for the respective treatment groups were recorded in the included excel study sheet. BID injections were spaced approximately 12-hours apart to maximize target coverage. Study animals received a total of 14 injections of vehicle or FTX-2865 over 8 days and were sacrificed approximately 1-hour after the final morning injection on day 8.
  • Blood samples for PK Approximately 100 ⁇ of blood sample was obtained via jugular vein or tail vein at each pre-defined time point. Blood samples were placed in pre- chilled collecting tubes treated with EDTA-K2 as anti -coagulant and placed on ice until centrifugation.
  • Plasma collection for PK assessment PK blood samples were centrifuged at 4°C, 3000g for 15 min within half an hour for plasma collection. Plasma samples were stored in polypropylene tubes or 96-well plates, quickly frozen on dry ice and stored at -70°C until LC/MS/MS analysis.
  • Muscle collection for PK and PD assessment Bilateral tibialis anterior and trapezius muscles were collected following blood collection by cardiac puncture. Each muscle from left and right sides was quickly weighed separately and placed in separate tubes, then snap frozen on dry ice. Muscles from one side were used for the measurement of compound concentration, those from the other side were sent to the sponsor for PD analysis. Dosing was staggered so that sample collection was carried out at approximately the same time at the end of the day.
  • Plasma Sample Preparation for LC/MS Analysis An aliquot of 10 plasma sample was protein precipitated with 150 IS solution (100 ng/mL Labetalol & 100 ng/mL Tolbutamide & 100 ng/mL Diclofenac in ACN), the mixture was vortex-mixed well and centrifuged at 4000 rpm for 15 min, 4 °C. An aliquot of 80 ⁇ ⁇ supernatant was transferred to sample plate and mixed with 80 ⁇ ⁇ water, then the plate was shaken at 800 rpm for 10 min. 1 ⁇ ⁇ supernatant was then injected for LC-MS/MS analysis.
  • Muscle sample preparation for LC/MS Analysis The muscle samples were homogenized in water in a 1 :4 ratio (w/v) using Omni bead ruptor. The homogenates were then used for the measurement of drug concentration. An aliquot of 20 muscle tissue homogenate was protein precipitated with 200 IS solution (100 ng/mL Labetalol & 100 ng/mL Tolbutamide & 100 ng/mL
  • Quantitation method The peak area of the test article in samples and in the standard solution sample was determined by LC/UV or LC-MS/MS method.
  • Method acceptance criteria Linearity: >75% STDs was back calculated to within ⁇ 20% of their nominal values ( ⁇ 25% for LLOQ) in biofluid and within 25% of their nominal values (30% for LLOQ) in tissue homogenate and feces sample.
  • QC > 67% all QCs was back calculated to within ⁇ 20% of their nominal values for biofluid and within 25% of their nominal values for tissue and feces samples.
  • Specificity The mean calculated concentration of analyte in the single blank matrix was less than 0.5 times of the LLOQ.
  • Sensitivity The LLOQ in biofluid and tissue homogenate was 1-3 ng/mL.
  • Carryover The mean calculated carryover concentration in the single blank matrix immediately after the highest standard injection was less than LLOQ. Protocol for Cryofracture, Lysis and Preparation of Muscle Tissue for Immunoassay Assessment of Target Engagement:
  • RIPA lysis buffer was prepared (R0278-500ML, Sigma, MO, USA). For 10ml, two Roche PhosSTOP phosphatase inhibitor tablets and one Roche EDTA-free protease inhibitor tablet were added. To the cryofractured material, 8 ⁇ 1 per mg of RIPA buffer were added to each tube and each tube was vortexed until the lysate was
  • the homogenized trapezius muscle lysate was assessed using an internally developed Meso Scale Discovery (MSD) multiplexed phospho MK2 / total MK2 immunoassay (Meso Scale Diagnostics, MD, USA). For each sample, 50 of muscle lysate, equal to 50 ⁇ g of protein, was loaded onto the MSD assay. Protein concentrations in muscle lysates were determined by a Bradford DC protein assay as described above. Samples were assessed in duplicate. Muscle samples were incubated on a pre-coated MSD plate overnight at 4°C while on an orbital shaker (300 rpm) and assessed the following morning.
  • MSD Meso Scale Discovery
  • cDNA was synthesized from the RNA template via reverse transcription.
  • the targeted transcripts were then pre-amplified in a 14-cycle PCR assay using diluted, human-specific TaqMan probes.
  • Gene expression was analyzed in a qPCR assay using the human specific TaqMan probes. The relative expression level was normalized to CDKNIB expression using 2 "ACt method.
  • Plasma and muscle concentration versus time were analyzed by non-compartmental approaches using the Phoenix WinNonlin 6.3 software (Cetera, NJ, USA).
  • CO, CLp, Vdss, Cmax, Tmax, T1 ⁇ 2, AUC(O-t), AUC(O-inf), MRT(O-t) , MRT(O-inf), %F and graphs of plasma and muscle concentration versus time profile and PD endpoints are reported using GraphPad Prizm software version 7 (CA, USA). Muscle PD was assessed via one-way ANOVA using GraphPad Prizm software version 7 (CA, USA). The effect of C6 vs.
  • A4 cell engraftment on MBD3L2 mRNA in xenografted muscles was assessed via two-tailed T-test using GraphPad Prizm software version 7 (CA, USA).
  • the effect of FTX-2865 vs. vehicle treatment on MBD3L2 mRNA in FSHD xenografted muscles was assessed via two-tailed T-test using GraphPad Prizm software version 7 (CA, USA).
  • Wild type myotubes were treated with DMSO control vehicle, and mature patient- derived FSHD myotubes that express DUX4 protein were treated with DMSO vehicle control or 1 ⁇ of a DUX4 sequence-directed antisense oligonucleotide (ASO; FTX-2) purchased from Exiqon. After treatment, the myotubes were lysed in 19.5 ⁇ ⁇ of Roche Real Time Ready Lysis Buffer, 0.25 of DNAse l (Ambion, AM2222), 0.25 of Protector RNase Inhibitor (Roche, 3335402001), and the RNA was collected in an RNeasy Micro Kit Master Mix.
  • ASO DUX4 sequence-directed antisense oligonucleotide
  • Expression levels of DUX4-regulated downstream genes was determined by real time PCR (ThermoFisher Scientific, 4484262), ZSCAN4 Taqman Assay (ThermoFisher Scientific, Hs00537549_ml, FAM-MGB), MYOG Taqman Assay (ThermoFisher Scientific, Hs01072232_ml, JUN- QSY), RPLP0 Taqman Assay (ThermoFisher Scientific, Hs99999902_m l), and/or LEUTX Taqman Assay (ThermoFisher Scientific, Hs00418470_ml). Ct values were extracted from QuantStudio Realtime PCR software, and Genedata was used to calculate relative levels of expression using POLR2A as a housekeeping gene.
  • FIG. 3A The data in FIG. 3A are grouped plate quality control data comparing expression of MBD3L2 mRNA in FSHD myotubes treated with DMSO control or 1 ⁇ DUX4 ASO, and healthy normal isogenic control myotubes.
  • FIG. 3A The data in FIG. 3A are grouped plate quality control data comparing expression of MBD3L2 mRNA in FSHD myotubes treated with DMSO control or 1 ⁇ DUX4 ASO, and healthy normal isogenic control myotubes.
  • FIG. 3B shows pharmacologic quality control data and dose dependent reduction of DUX4 and the downstream gene, MBD3L2, using different dilutions of the DUX4 ASO.
  • FIG. 3C shows plate-based assay statistics comparing FSHD myotubes treated with DMSO to WT: Z' is 0.512 and Signal to Noise (S/N) is 5.1, and FSHD myotubes treated with DMSO or DUX4 ASO: Z' is 0.319 and Signal to Noise (S/N) is 4.6.
  • Wild type myotubes and mature patient-derived FSHD myotubes that express DUX4 protein were treated with DMSO vehicle control or multiple concentrations of various ⁇ 38 ⁇ / ⁇ inhibitors with different ranges of isoform and kinome selectivity, including SB239063 (FIG. 4A), VX-702 (FIG. 4B), Pamapimod (FIG. 4C), and TAK-715 (FIG. 4D).
  • the control and treated cells were processed for realtime PCR quantification of MBD3L2 mRNA (DUX4 downstream gene) and myogenin (MYOG) mRNA (control) expression.
  • MBD3L2 mRNA DUX4 downstream gene
  • MYOG myogenin
  • p38 inhibitors e.g., Pamapimod
  • DUX4 mRNA and DUX4 downstream gene MBD3L2 mRNA expression without impacting myotube formation.
  • FTX000839 (Pamapimod) dose-dependently reduced both DUX4-fl and MBD3L2 downstream gene mRNA levels normalized to POLR2A mRNA, as measured by qPCR and Taqman in FSHD myotubes (FIG. 5A) without impacting differentiation into myotubes (FIG. 5B).
  • the data show that p38 inhibitors dose-dependently reduce MBD3L2 mRNA expression without impacting myogenin mRNA expression.
  • ⁇ 38 ⁇ MAPK14 85 and ⁇ 38 ⁇ MAPK14 86 siRNAs were transfected into patient FSHD myotubes as described in Materials and Methods.
  • the data shows that genomic reduction of p38a MAPK14 >50% specifically reduced DUX4 and downstream target genes, as exemplified by MBD3L2.
  • CRISPR gRNA targeting of MAPK14 or pLAM was conducted as described in Materials and Methods.
  • CRISPR gRNA targeted to MAPK14 or pLAM (polyadenylation signal sequence for DUX4) resulted in a reduction in expression of MBD3L2 but no MYOG.
  • the data indicates that genomic reduction of p38a MAPK14 specifically reduced DUX4 and downstream target genes, as exemplified by MBD3L2.
  • Immortalized FHSD myotubes were differentiated and treated with DMSO vehicle control or FTX-1821 at concentrations of 1 ⁇ , 0.33 ⁇ , 0.11 ⁇ , or 0.037 ⁇ . After 4 days, the cells were fixed and stained with antibodies directed against MHC or DAPI. See FIG. 8A. The nuclei in myotubes were quantified according to MHC staining (FIG. 8B). The results showed no changes in myotube formation or fusion after treatment with FTX- 1821 at concentrations tested.
  • Apoptosis was measured by active Caspase-3 levels in FSHD myotubes in vitro as described in Materials and Methods. Apoptosis was detected in a sporadic manner in a subset of myotubes in culture as shown by the white circles and magnified region in FIG. 9A.
  • RNA-seq profiling As shown in the heatmap of FIG. 10A, a number of differentially expressed genes were identified by RNA-seq profiling. The bar indicates the normalized changes observed, e.g., genes that were downregulated by FTX-1821 are enriched in samples treated with only DMSO. The expression of these genes was normalized upon treatment with FTX-1821 (1 ⁇ ) and closer resembled the observations in wild type cells. Calculated using standard RPKM expression values, the total gene signature was very small and defined at standard statistical cutoffs: 86/19,799 mRNA genes. DUX4-regulated gene signature was a majority of the total signature, and these genes are listed in FIG. 10A.
  • FIG. 10B shows the normalized reads, as described in Materials and Methods, of the DUX4 target genes that were downregulated upon treatment with FTX- 1821. Three independent replicates per group were analyzed.
  • MBD3L2 expression levels were reduced in all of the FSHD lines, resulting in levels similar to those measured in healthy controls, FTCE-396 and FTCE-014 (FIG. 11). This is evidence of DUX4 target gene reduction by p38 inhibitors across myotubes derived from diverse FSHDl genotypes and phenotypes (similar results were observed for FSHD2, data not shown).
  • FIG. 13 summarizes the genotypes and phenotypes of 13 FSHD l and 3 FSHD2 patient myoblasts used in the study.
  • the various FSHDl and FSHD2 myoblasts were treated with DMSO, FTX-1821 or FTX-839 (1 ⁇ ), and following treatment, mRNA expression levels of the DUX4 target gene, MBD3L2, were determined.
  • apoptosis was determined by measuring active caspase-3 in the FSHDl and FSHD2 lines.
  • Each of the various FSHDl and FSHD2 myoblasts showed a reduction of MBD3L2 (FIG. 14A, top 11 lines). The reduction resulted in expression levels similar to those in healthy control lines (CTRL- FTCE-014) (FIG. 14A, bottom 2 lines).
  • CTRL- FTCE-014 treatment with FTX-839 showed a reduction in apoptosis across both FSHDl and FSHD2 lines, to a level that was similar to the amount determined in a healthy control line (CTRL- FTCE-014) (FIG. 14B).
  • Pharmacodynamic analysis of p38 system target engagement in muscle tissue was performed by measuring the change in phospho MAP kinase-activated protein kinase 2 (MK2) to total MK2 ratio before and after drug treatment. All methods used are described in the Materials and Methods section.
  • FTX-1821 exhibited plasma pharmacokinetic properties similar to those described previously (Aston et al., 2009; data not shown). These studies additionally demonstrated rapid distribution of FTX-1821 to multiple muscles and plasma. Muscle to plasma exposure ratios were equal to or greater than 1 in the rat when clinically relevant plasma exposures were achieved.
  • the muscle concentrations of FTX-1821 achieved in the rat study are predicted to result in >70% reduction at Cmax in DUX4 dependent target genes in FSHD patient muscle biopsies based upon in vitro data in FSHD myotubes (above).
  • FSHD and control muscle xenograft mice were generated by xenografting C6 (FSHD) and A4 (control) IPSC-derived human immortalized isogeneic myoblast cell lines into the bilateral tibialis anterior (TA) muscles of approximately 8-week old male Nod-Rag mice as described by Sakellariou et al., 2016. Following the 4-week long engraftment and INMES procedure, the FSHD xenografted animals were treated with BID injections of either vehicle or FTX-2865 (10 mg/kg) for 8 days (a total of 14 injections) and were sacrificed at approximately the time of maximal plasma concentrations (Tmax) 1-hour after the final morning injection on Day 8.
  • Tmax maximal plasma concentrations
  • MBD3L2 was assessed by qPCR using a human specific probe and was normalized to the housekeeping gene CDKN1B.
  • pMK2 and MK2 protein concentrations were assessed by a quantitative MSD assay.
  • FTX-2865 Treatment of FSHD xenografted animals with the potent and selective p38 inhibitor, FTX-2865, produced p38 system target engagement, as measured by a change in phospho MAP kinase-activated protein kinase 2 (MK2) to total MK2 ratio of >50% in the TA and trapezius muscles of wild-type mice following repeated BID administration of a lOmg/kg dose given via intraperitoneal (IP) injection (data not shown).
  • MK2 phospho MAP kinase-activated protein kinase 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
EP18797227.8A 2017-10-05 2018-10-05 Use of p38 inhibitors to reduce expression of dux4 Pending EP3692144A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762568754P 2017-10-05 2017-10-05
US201762568673P 2017-10-05 2017-10-05
US201862682563P 2018-06-08 2018-06-08
US201862682565P 2018-06-08 2018-06-08
PCT/US2018/054638 WO2019071144A1 (en) 2017-10-05 2018-10-05 USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION

Publications (1)

Publication Number Publication Date
EP3692144A1 true EP3692144A1 (en) 2020-08-12

Family

ID=63963605

Family Applications (3)

Application Number Title Priority Date Filing Date
EP18797227.8A Pending EP3692144A1 (en) 2017-10-05 2018-10-05 Use of p38 inhibitors to reduce expression of dux4
EP18792812.2A Active EP3691620B1 (en) 2017-10-05 2018-10-05 P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
EP22186319.4A Pending EP4159212A1 (en) 2017-10-05 2018-10-05 P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP18792812.2A Active EP3691620B1 (en) 2017-10-05 2018-10-05 P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
EP22186319.4A Pending EP4159212A1 (en) 2017-10-05 2018-10-05 P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd

Country Status (28)

Country Link
US (5) US11479770B2 (es)
EP (3) EP3692144A1 (es)
JP (5) JP2021501130A (es)
KR (2) KR20200066655A (es)
CN (4) CN114748622B (es)
AU (2) AU2018346709A1 (es)
BR (2) BR112020006169A2 (es)
CA (4) CA3128468A1 (es)
CL (3) CL2020000911A1 (es)
CO (2) CO2020005351A2 (es)
DK (1) DK3691620T3 (es)
EC (1) ECSP20024210A (es)
ES (1) ES2927715T3 (es)
HR (1) HRP20221196T1 (es)
HU (1) HUE060024T2 (es)
IL (2) IL273589B (es)
LT (1) LT3691620T (es)
MX (2) MX2020003961A (es)
NZ (1) NZ762856A (es)
PH (2) PH12020550195A1 (es)
PL (1) PL3691620T3 (es)
PT (1) PT3691620T (es)
RS (1) RS63581B1 (es)
SG (2) SG10202110259QA (es)
TW (1) TWI793191B (es)
UY (1) UY37918A (es)
WO (2) WO2019071147A1 (es)
ZA (1) ZA202002315B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US20210038653A1 (en) * 2018-02-02 2021-02-11 Fred Hutchinson Cancer Research Center Methods for treating facioscapulohumeral muscular dystrophy
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
WO2021105474A1 (en) 2019-11-29 2021-06-03 Facio Intellectual Property B.V. New compounds for treatment of diseases related to dux4 expression
WO2021105481A1 (en) 2019-11-29 2021-06-03 Facio Intellectual Property B.V. Novel compounds for treatment of diseases related to dux4 expression
CN111004802A (zh) * 2019-12-31 2020-04-14 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） 特异抑制p38MAPK基因表达的shRNA重组载体构建方法与应用
WO2022056266A2 (en) 2020-09-11 2022-03-17 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
US20240342148A1 (en) * 2021-07-27 2024-10-17 Fulcrum Therapeutics, Inc. Methods of treating facioscapulohumeral muscular dystrophy with losmapimod
WO2024145662A1 (en) * 2022-12-30 2024-07-04 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors

Family Cites Families (451)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5670527A (en) 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
JP2001508395A (ja) 1996-01-11 2001-06-26 スミスクライン・ビーチャム・コーポレイション 新規シクロアルキル置換イミダゾール
ZA97175B (en) 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
WO1997032583A1 (en) 1996-03-08 1997-09-12 Smithkline Beecham Corporation Use of csaidtm compounds as inhibitors of angiogenesis
JP2000510327A (ja) 1996-03-12 2000-08-15 スミスクライン・ビーチャム・コーポレイション 医薬的に活性な化合物の同定方法
WO1997033883A1 (en) 1996-03-13 1997-09-18 Smithkline Beecham Corporation Novel pyrimidine compounds useful in treating cytokine mediated diseases
US6235760B1 (en) 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
US6096739A (en) 1996-03-25 2000-08-01 Smithkline Beecham Corporation Treatment for CNS injuries
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
WO1998028292A1 (en) 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
US5965583A (en) 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US6610695B1 (en) 1997-06-19 2003-08-26 Smithkline Beecham Corporation Aryloxy substituted pyrimidine imidazole compounds
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
AR016294A1 (es) 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
CN1279682A (zh) 1997-10-20 2001-01-10 霍夫曼-拉罗奇有限公司 双环激酶抑制剂
US6162613A (en) 1998-02-18 2000-12-19 Vertex Pharmaceuticals, Inc. Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
EP1075467B1 (en) 1998-05-05 2005-03-30 F. Hoffmann-La Roche Ag Pyrazole derivatives as p-38 map kinase inhibitors
US6316466B1 (en) 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
US6867209B1 (en) 1998-05-22 2005-03-15 Scios, Inc. Indole-type derivatives as inhibitors of p38 kinase
NZ508790A (en) 1998-05-22 2003-10-31 Scios Inc Heterocyclic compounds and methods to treat cardiac failure and other disorders
US6448257B1 (en) 1998-05-22 2002-09-10 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6589954B1 (en) 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6340685B1 (en) 1998-05-22 2002-01-22 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
JP2002516322A (ja) 1998-05-22 2002-06-04 スミスクライン・ビーチャム・コーポレイション 新規２−アルキル置換イミダゾール化合物
JP2002517486A (ja) 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
EP1112070B1 (en) 1998-08-20 2004-05-12 Smithkline Beecham Corporation Novel substituted triazole compounds
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP2002526482A (ja) 1998-09-18 2002-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
EP1119254A4 (en) 1998-10-07 2004-05-12 Smithkline Beecham Corp STROKE TREATMENT
DE69914357T2 (de) 1998-11-04 2004-11-11 Smithkline Beecham Corp. Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
AU765473B2 (en) 1999-04-23 2003-09-18 Takeda Pharmaceutical Company Limited 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
ATE376547T1 (de) 1999-05-21 2007-11-15 Scios Inc Derivate des indol-typs als p38 kinase inhibitoren
ATE312823T1 (de) 1999-07-09 2005-12-15 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
US6541477B2 (en) 1999-08-27 2003-04-01 Scios, Inc. Inhibitors of p38-a kinase
KR20020032591A (ko) 1999-09-17 2002-05-03 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 라이노바이러스 감염에서의 ｃｓａｉｄ의 용도
JP3961830B2 (ja) 1999-10-21 2007-08-22 エフ．ホフマン−ラ ロシュ アーゲー ｐ３８プロテインキナーゼのインヒビターとしてのヘテロアルキルアミノ置換二環式窒素複素環
TR200201058T2 (tr) 1999-10-21 2002-07-22 F.Hoffmann-La Roche Ag P38 protein kinaz inhibitörleri olarak, alkilaminoyla ornatılmış bisiklik, azotlu heterosikller
WO2001038312A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS
ES2241675T3 (es) 1999-11-23 2005-11-01 Smithkline Beecham Corporation Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de cspb/p38 quinasa.
JP2003517471A (ja) 1999-11-23 2003-05-27 スミスクライン・ビーチャム・コーポレイション ３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オンおよびそのＣＳＢＰ／ｐ３８キナーゼ阻害剤としての使用
AU1782301A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
AU2735201A (en) 1999-12-28 2001-07-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
AU2001241927A1 (en) 2000-02-28 2001-09-12 Scios Inc. Inhibitors of p38-alpha kinase
AR030053A1 (es) 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
US6565880B2 (en) 2000-07-24 2003-05-20 Boehringer Ingelheim Pharmaceuticals, Inc. Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
CN1275964C (zh) 2000-08-31 2006-09-20 霍夫曼-拉罗奇有限公司 作为细胞增殖抑制剂的7－氧代吡啶并嘧啶
MXPA03001733A (es) 2000-08-31 2003-05-27 Hoffmann La Roche 7-oxo-piridopirimidinas.
WO2002032862A2 (en) 2000-10-19 2002-04-25 Smithkline Beecham Corporation Use of p38 inhibitors for the treatment of smoke inhalation
AU2002248269A1 (en) 2000-10-19 2002-08-12 Smithkline Beecham Corporation Use of p38 inhibitors for the treatment of inflammation-enhanced cough
EP1333833B1 (en) 2000-10-23 2011-08-24 GlaxoSmithKline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compound for the treatment of CSBP/p38 kinase mediated diseases
JP2004522713A (ja) 2000-11-17 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー ｐ３８キナーゼ関連疾患の処置方法およびキナーゼインヒビターとして有用なピロロトリアジン化合物
CA2429258A1 (en) 2000-11-20 2002-06-13 Scios Inc. Piperidine/piperazine-type inhibitors of p38 kinase
CA2429382A1 (en) 2000-11-20 2002-06-06 Scios Inc. Indole-type inhibitors of p38 kinase
CA2429605A1 (en) 2000-11-20 2002-05-30 Scios Inc. Indol derivative and their use as inhibitors of p38 kinase
US20020165286A1 (en) 2000-12-08 2002-11-07 Hanne Hedeman Dermal anti-inflammatory composition
WO2002058695A1 (en) 2000-12-20 2002-08-01 Merck & Co., Inc. (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
WO2002064594A2 (en) 2001-02-12 2002-08-22 F. Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
EP1370253B8 (en) 2001-02-28 2008-11-26 Temple University of the Commonwealth System of Higher Education Use of alpha, beta unsaturated aryl sulfones for protecting cells and tissues from ionizing radiation toxicity
ES2251582T3 (es) 2001-03-09 2006-05-01 Pfizer Products Inc. Compuestos antiinflamatorios de bencimidazol.
ATE323701T1 (de) 2001-03-09 2006-05-15 Pfizer Prod Inc Triazolopyridine als entzündungshemmende mittel
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
AU2002303145A1 (en) 2001-03-23 2002-10-08 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076984A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076463A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
ATE304009T1 (de) 2001-04-04 2005-09-15 Pfizer Prod Inc Neue benzotriazole mit entzündungshemmender wirkung
US20040136949A1 (en) 2001-04-24 2004-07-15 Matthias Grell Combination therapy using anti-angiogenic agents and tnf alpha
WO2002090360A1 (en) 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
EP1392300A1 (en) 2001-05-11 2004-03-03 Vertex Pharmaceuticals Incorporated 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
DE60221392T2 (de) 2001-05-24 2008-04-17 Eli Lilly And Co., Indianapolis Neue pyrrolderivate als pharmazeutische mittel
ATE415162T1 (de) 2001-06-11 2008-12-15 Vertex Pharma Isochinolin-inhibitoren von p38
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
JP4510442B2 (ja) 2001-06-26 2010-07-21 ブリストル−マイヤーズ スクイブ カンパニー ＴＮＦ−α発現のＮ−ヘテロ環インヒビター
DE60219793T2 (de) 2001-07-11 2008-01-24 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Verfahren zur Behandlung von Cytokin-Vermittelten Erkrankungen
CA2454913A1 (en) 2001-08-20 2003-02-27 Boehringer Ingelheim Pharmaceuticals, Inc. Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin
AU2002331179B2 (en) 2001-08-30 2008-04-17 F. Hoffmann-La Roche Ag Aminopyrrole compounds as antiinflammatory agents
US20040235808A1 (en) 2001-09-21 2004-11-25 Jiabing Wang Androstanes as androgen receptor modulators
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
WO2003032894A2 (en) 2001-10-12 2003-04-24 Pfizer Products Inc. Method of monitoring neuroprotective treatment
GB0124928D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
JP2005511593A (ja) 2001-11-08 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 骨粗鬆症を治療するための組成物及び方法
US20040009990A1 (en) 2001-11-09 2004-01-15 Higgins Linda S. Method to treat cystic fibrosis
US20050261836A1 (en) 2001-12-05 2005-11-24 Wuyi Meng Crystal structure of mitogen-activated protein kinase-activated protein kinase 2 and binding pockets thereof
US20030118575A1 (en) 2001-12-11 2003-06-26 Boehringer Ingelheim Pharmaceuticals, Inc. Method for administering BIRB 796 BS
AU2003206382B2 (en) 2002-01-03 2008-01-24 Smithkline Beecham Corporation Novel pharmaceutical dosage forms and method for producing same
US7605152B2 (en) 2002-01-15 2009-10-20 Merck & Co., Inc. 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators
DE10203749A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203753A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203741A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20040023961A1 (en) 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
ATE485275T1 (de) 2002-02-12 2010-11-15 Glaxosmithkline Llc Nicotinamide und deren verwendung als p38 inhibitoren
ATE410429T1 (de) 2002-03-07 2008-10-15 Hoffmann La Roche Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase
AU2003218235B2 (en) 2002-03-13 2008-05-15 Merck Sharp & Dohme Corp. Fluorinated 4-azasteroid derivatives as androgen receptor modulators
WO2003079986A2 (en) 2002-03-18 2003-10-02 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
US6900208B2 (en) 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
RU2310657C2 (ru) 2002-04-03 2007-11-20 Ф.Хоффманн-Ля Рош Аг Имидазоконденсированные соединения и фармацевтическая композиция, содержащая их
BR0309009A (pt) 2002-04-05 2005-03-22 Boehringer Ingelheim Pharma Método para o tratamento de hipersecreção de muco
US20030225089A1 (en) 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
DE10216339A1 (de) 2002-04-13 2003-10-23 Boehringer Ingelheim Pharma Neue Ester hydroxy-substituierter Stickstoffheterocyclen, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2003087394A1 (en) 2002-04-15 2003-10-23 Glaxo Group Limited A method of identifying a modudator for a serine/theronine kinase
BR0309053A (pt) 2002-04-19 2005-02-22 Smithkline Beecham Corp Compostos
EP1503996B1 (en) 2002-04-23 2008-12-24 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
DK1497019T3 (en) 2002-04-23 2015-08-03 Bristol Myers Squibb Co PYRROLO-TRIAZINANILINE COMPOSITIONS USED AS KINase INHIBITORS
US7388009B2 (en) 2002-04-23 2008-06-17 Bristol-Myers Squibb Company Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
US20050131005A1 (en) 2002-04-30 2005-06-16 Jiabing Wang 4-azasteroid derivatives as androgen receptor modulators
GB0209891D0 (en) 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
US7008958B2 (en) 2002-05-21 2006-03-07 Bristol-Myers Squibb Company 2-substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same
JP4245561B2 (ja) 2002-06-11 2009-03-25 メルク エンド カムパニー インコーポレーテッド （ハロ−ベンゾカルボニル）複素２環ｐ３８キナーゼ阻害剤
DE60310730T2 (de) 2002-07-09 2007-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
EP1575506A4 (en) 2002-07-25 2008-04-23 Scios Inc METHOD FOR IMPROVING LUNG FUNCTION WITH TGF-BETA INHIBITORS
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
JP4252534B2 (ja) 2002-08-06 2009-04-08 エフ．ホフマン−ラ ロシュ アーゲー ｐ−３８ＭＡＰキナーゼインヒビターとしての６−アルコキシ−ピリド−ピリミジン類
US6872726B2 (en) 2002-08-08 2005-03-29 Boehringer Ingelheim Pharmaceuticals Inc. Fluorinated di-aryl urea compounds
AU2003256297A1 (en) 2002-08-09 2004-02-25 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
US20040110755A1 (en) 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
CA2496445A1 (en) 2002-08-14 2004-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
EP1539121A4 (en) 2002-08-29 2008-08-13 Scios Inc METHOD OF REQUESTING OSTEOGENESIS
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US20040092547A1 (en) 2002-08-30 2004-05-13 Pfizer Inc Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7037923B2 (en) 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
AU2003253188A1 (en) 2002-08-30 2004-03-19 Pfizer Products Inc. Novel processes and intermediates for preparing triazolo-pyridines
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
AU2003268464A1 (en) 2002-09-03 2004-03-29 Scios Inc. INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
JP2006503025A (ja) 2002-09-05 2006-01-26 サイオス インク． ｐ３８ＭＡＰキナーゼの抑制による疼痛治療
US20050288503A1 (en) 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
US7115644B2 (en) 2002-09-13 2006-10-03 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds
WO2004026871A1 (en) 2002-09-17 2004-04-01 Eli Lilly And Company Novel pyrazolopyridine derivatves as pharmaceutical agents
WO2004029040A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. 3,4-disubstituted pyrroles and their for use in treating inflammatory diseases
WO2004033632A2 (en) 2002-10-04 2004-04-22 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
US20050288299A1 (en) 2002-10-09 2005-12-29 Mavunkel Babu J Azaindole derivatives as inhibitors of p38 kinase
EP1560582A4 (en) 2002-10-09 2008-03-12 Scios Inc AZAINDOL DERIVATIVES AS INHIBITORS OF THE p38 KINASE
WO2004041277A1 (en) 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
EP1565475B1 (en) 2002-11-18 2009-04-08 F. Hoffmann-La Roche Ag Diazinopyrimidines and their use as protein kinase inhibitors
DE10255040A1 (de) 2002-11-26 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbaminsäureester mit anticholinerger Wirksamkeit
AU2003299652A1 (en) 2002-12-06 2004-06-30 Scios Inc. Methods for treating diabetes
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
CN1771234A (zh) 2003-02-05 2006-05-10 布里斯托尔-迈尔斯斯奎布公司 吡咯并三嗪激酶抑制剂的制备方法
MXPA05008450A (es) 2003-02-10 2005-10-18 Vertex Pharma Procesos para la preparacion de n-heteroaril-n-aril-aminas mediante reaccion de un ester de acido n-aril-carbamico con un halo-heteroarilo y procesos analogos.
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
DE602004001676T2 (de) 2003-02-14 2007-08-30 Pfizer Products Inc., Groton Triazolo-Pyridine als entzündungshemmende Verbindungen
MXPA05008612A (es) 2003-02-14 2005-12-05 Smithkline Beecham Corp Compuestos novedosos.
TWI325865B (en) 2003-02-27 2010-06-11 Palau Pharma Sa Pyrazolopyridine derivatives
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
MXPA05009459A (es) 2003-03-03 2006-05-17 Array Biopharma Inc Inhibidores de p38 y sus metodos de uso.
US7030112B2 (en) 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
ES2279361T3 (es) 2003-04-16 2007-08-16 F. Hoffmann-La Roche Ag Derivados de (6-(fenoxi)-pirido-3,4-dipirimidin-2-il)-amina como inhibidores de p38 kinasa para el tratamiento de estados inflamatorios tal como artritis reumatoide.
MXPA05011103A (es) 2003-04-16 2005-12-12 Hoffmann La Roche Compuestos de quinazolina.
PT1618092E (pt) 2003-05-01 2010-11-22 Bristol Myers Squibb Co Compostos de pirazol-amida substituídos com arilo úteis enquanto inibidores de cinase
GB0320244D0 (en) 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
WO2004100874A2 (en) 2003-05-07 2004-11-25 Merck & Co., Inc. Androgen receptor modulators and methods of use thereof
MXPA05013059A (es) 2003-06-04 2006-03-02 Pfizer Derivados de 2-amino-piridina como agonistas del adrenoceptor beta-2.
ATE517872T1 (de) 2003-06-26 2011-08-15 Novartis Ag Fünfgliedrige p38-kinaseinhibitoren auf heterocyclusbasis
CN1816370A (zh) 2003-06-30 2006-08-09 麦克公司 用作雄激素受体调节剂的17－乙酰氨基－4－氮杂甾族化合物衍生物
CA2530182A1 (en) 2003-06-30 2005-01-20 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
WO2005009367A2 (en) 2003-07-17 2005-02-03 Ambit Biosciences Corporation Treatment of diseases with kinase inhibitors
GB0317482D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US7153870B2 (en) 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0317484D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
GB0317516D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
CN1838958A (zh) 2003-08-22 2006-09-27 贝林格尔·英格海姆药物公司 治疗慢性阻塞性肺病和肺动脉高血压的方法
US20050053600A1 (en) 2003-09-09 2005-03-10 Lane Thomas E. Methods for treating rheumatoid arthritis
EP1663228A4 (en) 2003-09-10 2010-10-06 Merck Sharp & Dohme USE OF 17-HETEROCYCLIC-4-AZASTEROIDIAN DERIVATIVES AS MODULATORS OF THE ANDROGEN RECEPTOR
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
CA2540828A1 (en) 2003-09-30 2005-04-14 Scios Inc. Heterocyclic amides and sulfonamides
WO2005032551A1 (en) 2003-09-30 2005-04-14 Scios Inc. TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
ES2281843T3 (es) 2003-11-13 2007-10-01 F. Hoffmann-La Roche Ag Pirido-7-pirimidin-7-onas sustituidas con hidroxialquilo.
EP1538201A1 (en) 2003-12-02 2005-06-08 F.Hoffmann-La Roche Ag Method for the recombinant production and purification of protein kinases
WO2005063715A1 (en) 2003-12-18 2005-07-14 Boehringer Ingelheim Pharmaceuticals, Inc. Polymorph of birb 796, a p38map kinase inhibitor
GB0329275D0 (en) 2003-12-18 2004-01-21 Merck Sharp & Dohme Therapeutic treatment
AU2004305318A1 (en) 2003-12-18 2005-07-07 Pfizer Products Inc. Methods of treating acute inflammation in animals with p38 MAP kinase inhibitors
US20060052390A1 (en) 2003-12-24 2006-03-09 Scios, Inc. Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
US20060058296A1 (en) 2003-12-24 2006-03-16 Scios, Inc. Treatment of osteolytic lesions associated with multiple myeloma by inhibition of p38 map kinase
US20060079461A1 (en) 2003-12-24 2006-04-13 Scios, Inc. Treatment of multiple myeloma by inhibition of p38 MAP kinase
CN1921864A (zh) 2003-12-24 2007-02-28 西奥斯公司 使用TGF－β抑制剂治疗神经胶质瘤
GB0402140D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402138D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
BRPI0507198A (pt) 2004-01-30 2007-06-26 Merck Patent Gmbh derivados de bisariluréia
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402143D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
US7863310B2 (en) 2004-02-03 2011-01-04 Eli Lilly And Company Kinase inhibitors
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
CA2557398A1 (en) 2004-02-26 2005-09-09 Hans-Peter Buchstaller Benzimidazolyl derivatives as kinase inhibitors
RU2006134021A (ru) 2004-02-27 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные гетероарил-конденсированного пиразола
KR20060114022A (ko) 2004-02-27 2006-11-03 에프. 호프만-라 로슈 아게 인다졸 유도체 및 그들을 함유하는 약학 조성물
AU2005227192A1 (en) 2004-03-11 2005-10-06 Kythera Biopharmaceuticals, Inc. Compositions and methods for preventing and treating skin and hair conditions
EP1574501A1 (en) 2004-03-11 2005-09-14 Pfizer Limited Quinolinone derivatives, pharmaceutical compositions containing them and their use
EP1577291A1 (en) 2004-03-17 2005-09-21 Pfizer Limited Phenylethanolamine derivatives as beta-2 agonists
EP1577292A1 (en) 2004-03-17 2005-09-21 Pfizer Limited Phenylaminoethanol derivatives as beta2 receptor agonists
EP1742631A4 (en) 2004-04-28 2009-11-11 Merck & Co Inc FLUORATED 4-AZASTEROIDS AS ANDROGEN RECEPTOR MODULATORS
WO2005110455A2 (en) 2004-05-13 2005-11-24 Intermune, Inc. Combination therapy for treating hepatitis virus infection
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
SI1761520T1 (sl) 2004-06-23 2008-10-31 Lilly Co Eli Inhibitorji kinaze
EP1609789A1 (en) 2004-06-23 2005-12-28 Eli Lilly And Company Ureido-pyrazole derivatives and their use as kinase inhibitors
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
TW200618803A (en) 2004-08-12 2006-06-16 Bristol Myers Squibb Co Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
GEP20104973B (en) 2004-08-12 2010-04-26 Pfizer Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
AU2005280334A1 (en) 2004-08-25 2006-03-09 Merck Sharp & Dohme Corp. Androgen receptor modulators
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
PE20060493A1 (es) 2004-10-05 2006-09-03 Smithkline Beecham Corp Compuestos derivados de bifenil (di o tri) carboxamidas como inhibidores de serina/treonina quinasa p38
CA2584185C (en) 2004-10-13 2014-07-15 Frank Stieber Heterocyclic substituted bisarylurea derivates as kinase inhibitors
CA2583217C (en) 2004-10-18 2011-05-31 Amgen Inc. 1,3,4-thiadiazole compounds as protein kinase inhibitors
CA2585276A1 (en) 2004-10-29 2006-06-08 Merck & Co., Inc. N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
WO2006055302A2 (en) 2004-11-04 2006-05-26 Scios Inc. Method of treating myelodysplastic syndromes
WO2006048266A2 (en) 2004-11-04 2006-05-11 Roche Diagnostics Gmbh Gene expression profiling of leukemias with mll gene rearrangements
GB0425057D0 (en) 2004-11-12 2004-12-15 Pfizer Ltd L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide
WO2006051373A1 (en) 2004-11-12 2006-05-18 Pfizer Limited Compounds for the treatment of diseases
WO2006055381A2 (en) 2004-11-16 2006-05-26 Merck & Co., Inc. Prodrugs of (2r)-2-propyloctanoic acid for treatment of stroke
US20080139614A1 (en) 2004-11-23 2008-06-12 Seabrook Guy R Treatment Of Stroke With Histamine H3 Inverse Agonists Or Histamine H3 Antagonists
US20060111416A1 (en) 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
US20070224662A1 (en) 2004-12-17 2007-09-27 Jun Luo Post-translational modification of proteins in cell-free expression systems
PE20061155A1 (es) 2004-12-24 2006-12-16 Boehringer Ingelheim Int Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas
US20060154939A1 (en) 2004-12-24 2006-07-13 Boehringer Ingelheim International Gmbh Medicaments for the Treatment or Prevention of Fibrotic Diseases
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
ATE538118T1 (de) 2004-12-28 2012-01-15 Aska Pharm Co Ltd Pyrimidinylisoxazolderivat
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
ATE469893T1 (de) 2005-02-28 2010-06-15 Merckle Gmbh 2-sulfinyl- und 2-sulfonyl-substituierte imidazolderivate und deren verwendung als cytokininhibitoren
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
JP2008535822A (ja) 2005-03-25 2008-09-04 グラクソ グループ リミテッド 新規化合物
AR053346A1 (es) 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
US20060235020A1 (en) 2005-04-18 2006-10-19 Soojin Kim Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
TW200716561A (en) 2005-05-11 2007-05-01 Array Biopharma Inc P38 inhibitors and methods of use thereof
WO2006127678A2 (en) 2005-05-23 2006-11-30 Smithkline Beecham Corporation Inhibition of p38 mark for treatment of obesity
GB0512429D0 (en) 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
US20070032506A1 (en) 2005-07-02 2007-02-08 Peter Giannousis Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
US20090088458A1 (en) 2005-08-02 2009-04-02 Meissner Robert S N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators
JP5113751B2 (ja) 2005-08-12 2013-01-09 メルク・シャープ・エンド・ドーム・コーポレイション ｐ３８キナーゼ阻害剤として有用な二環性複素環化合物
EP1928843A1 (en) 2005-08-22 2008-06-11 Amgen, Inc Bis-aryl urea compounds for the treatment of protein kinase-mediated diseaes
CN101243088B (zh) 2005-08-25 2011-06-29 霍夫曼-拉罗奇有限公司 p38 MAP激酶抑制剂及使用它的方法
EP1919877A1 (en) 2005-08-25 2008-05-14 F.Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
JP2009506006A (ja) 2005-08-25 2009-02-12 エフ．ホフマン−ラ ロシュ アーゲー ｐ３８ＭＡＰキナーゼ阻害剤およびその使用方法
CA2620104A1 (en) 2005-08-25 2007-03-01 F. Hoffman-La Roche Ag Fused pyrazole as p38 map kinase inhibitors
BRPI0615272A2 (pt) 2005-08-25 2009-08-04 Hoffmann La Roche inibidores de p38 map kinase e métodos para uso dos mesmos
EP1919919A1 (en) 2005-09-01 2008-05-14 Astellas Pharma Inc. Pyridazinone derivatives used for the treatment of pain
SI1928821T1 (sl) 2005-09-21 2009-04-30 Pfizer Ltd Derivati karboksamida kot antagonisti muskarinskih receptorjev
CA2623063A1 (en) 2005-09-26 2007-04-05 Merck & Co., Inc. N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamides as androgen receptor modulators
WO2007045989A1 (en) 2005-10-20 2007-04-26 Pfizer Limited Pyridyl derivatives useful as h3 ligands
DOP2006000233A (es) 2005-10-28 2007-06-15 Lilly Co Eli Inhibidores de cinasa
AR056582A1 (es) 2005-10-28 2007-10-10 Lilly Co Eli COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE
WO2007056016A2 (en) 2005-11-02 2007-05-18 Kemia, Inc. Bisamide cytokine inhibitors
EP1945639A1 (en) 2005-11-04 2008-07-23 Pfizer Limited Tetrahydronaphthyridine derivative
AU2006313430B2 (en) 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
PE20070823A1 (es) 2005-11-15 2007-08-09 Glaxo Group Ltd Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
WO2007075896A2 (en) 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
ES2389062T3 (es) 2006-01-18 2012-10-22 Amgen, Inc Compuestos de tiazol como inhibidores de proteína cinasa B (PKB)
CN101415685B (zh) 2006-01-31 2011-08-24 阿雷生物药品公司 激酶抑制剂及其使用方法
WO2007091152A1 (en) 2006-02-09 2007-08-16 Pfizer Limited Triazolopyridine compounds
EP1987022A1 (en) 2006-02-10 2008-11-05 Pfizer Products Inc. Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
KR20080100484A (ko) 2006-03-07 2008-11-18 버텍스 파마슈티칼스 인코포레이티드 류마티스관절염 치료용 ｖｘ-702의 용도
BRPI0708644A2 (pt) 2006-03-07 2011-06-07 Bristol-Myers Squibb Company compostos de pró-fármaco de anilina de pirrolotriazina úteis como inibidores de cinase
AU2007228511A1 (en) 2006-03-20 2007-09-27 Pfizer Limited Amine derivatives
EP2029581A1 (en) 2006-03-29 2009-03-04 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP2009533362A (ja) 2006-04-12 2009-09-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キナーゼ媒介性疾患を治療するための複素環式置換ビスアリール尿素のｎ−オキシド
WO2007124181A2 (en) 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
AU2007257959A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
GB0612026D0 (en) 2006-06-16 2006-07-26 Smithkline Beecham Corp New use
JP2009542816A (ja) 2006-06-16 2009-12-03 グラクソ グループ リミテッド 新規化合物
US20090318424A1 (en) 2006-06-16 2009-12-24 Mauro Corsi Novel compounds
JP2009542817A (ja) 2006-06-16 2009-12-03 グラクソ グループ リミテッド 新規化合物
EP2036905B1 (en) 2006-06-28 2012-12-12 ASKA Pharmaceutical Co., Ltd. Pyridylisoxazole derivative
EP2044957A4 (en) 2006-06-28 2011-01-05 Aska Pharm Co Ltd TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE
WO2008011032A1 (en) 2006-07-17 2008-01-24 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
WO2008013823A2 (en) 2006-07-26 2008-01-31 Scios Inc. Co-crystals of (2r-trans)-6-chloro-5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n,1-trimethyl-alpha-oxo-1h-indole-3-acetamide
CA2659222C (en) 2006-07-28 2012-01-31 Onconova Therapeutics, Inc. Formulations of radioprotective .alpha., .beta. unsaturated aryl sulfones
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
WO2008024391A1 (en) 2006-08-22 2008-02-28 Scios Inc. Pharmaceutical formulations of an indole-type derivative and related methods of use
BRPI0719270A2 (pt) 2006-10-04 2014-03-11 Pfizer Ltd Derivados de sulfonamida como agonistas adrenérgicos e antagonistas muscarínicos
ES2377821T3 (es) 2006-10-11 2012-04-02 Amgen Inc. Compuestos de imidazo- y triazolo-piridina y métodos de uso de los mismos.
WO2008048540A2 (en) 2006-10-18 2008-04-24 Merck & Co., Inc. 2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators
US20100099651A1 (en) 2006-10-26 2010-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
WO2008071665A1 (en) 2006-12-12 2008-06-19 Smithkline Beecham Corporation A nicotinamide derivative useful as p38 kinase inhibitor
WO2008071664A1 (en) 2006-12-12 2008-06-19 Smithkline Beecham Corporation Nicotinamide derivative used as a p38 kinase inhibitor
CA2670730A1 (en) 2006-12-13 2008-06-26 Gilead Sciences, Inc. Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction
CA2672256C (en) 2006-12-13 2011-08-30 Pfizer Products Inc. Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-methyl-2-oxopyridin-1(2h)-yl)-n,4-dimethylbenzamide
JP2010513370A (ja) 2006-12-19 2010-04-30 エフ．ホフマン−ラ ロシュ アーゲー ピラゾロ［３，４−ｄ］ピリミジンｐ３８ＭＡＰキナーゼインヒビター
WO2008079857A1 (en) 2006-12-20 2008-07-03 Bristol-Myers Squibb Company Crystalline forms of aryl-substituted pyrazole-amide compounds
WO2008089034A2 (en) 2007-01-11 2008-07-24 Kemia, Inc. Cytokine inhibitors
WO2008098096A1 (en) 2007-02-08 2008-08-14 Boehringer Ingelheim International Gmbh Anti-cytokine heterocyclic compounds
AU2008219165A1 (en) 2007-02-16 2008-08-28 Merck Sharp & Dohme Corp. Compositions and methods for potentiated activity of biologicaly active molecules
EP2123255B1 (en) 2007-02-16 2013-05-15 ASKA Pharmaceutical Co., Ltd. Pharmaceutical composition containing fine particle oil-based suspension
WO2008104473A2 (en) 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
ES2364727T3 (es) 2007-03-16 2011-09-13 Pfizer Limited Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2,2-difenilhexanamida.
WO2008137176A1 (en) 2007-05-07 2008-11-13 Amgen Inc. Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use
CA2685597C (en) 2007-05-07 2012-10-02 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators, process for their preparation, and their pharmaceutical use
AU2008276512A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
WO2009015000A1 (en) 2007-07-25 2009-01-29 Array Biopharma Inc. Pyrazole urea derivatives used as kinase inhibitors
CA2699463A1 (en) 2007-09-14 2009-03-19 Pfizer Limited Novel compounds active as muscarinic receptor antagonists
US8314131B2 (en) 2007-09-21 2012-11-20 Amgen Inc. Triazole fused heteroaryl compounds and methods of use thereof
CN101878221B (zh) 2007-11-30 2014-04-02 辉瑞有限公司 糖皮质激素受体激动剂
GB0724258D0 (en) 2007-12-12 2008-01-30 Glaxo Group Ltd Novel combinations
WO2009074518A1 (en) 2007-12-12 2009-06-18 Glaxo Group Limited Combinations of prolinamide p2x7 modulators with further therapeutic agents
WO2009078992A1 (en) 2007-12-17 2009-06-25 Amgen Inc. Linear tricyclic compounds as p38 kinase inhibitors
EP2235537A2 (en) 2008-01-25 2010-10-06 Bristol-Myers Squibb Pharma Company Identification of predictive markers of response to dasatinib in human colon cancer
CA2716124A1 (en) 2008-02-20 2009-08-27 Boehringer Ingelheim International Gmbh Powder inhalers
US8367671B2 (en) 2008-03-21 2013-02-05 Amgen Inc. Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents
JP2009263234A (ja) 2008-04-21 2009-11-12 Ranbaxy Lab Ltd ホスホジエステラーゼタイプｉｖ阻害剤の組成物
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
JP2011525184A (ja) 2008-06-20 2011-09-15 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なトリアゾロピリジン化合物
US8338604B2 (en) 2008-06-20 2012-12-25 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
WO2009158450A1 (en) 2008-06-25 2009-12-30 Bristol-Myers Squibb Company Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, preparation and use thereof
WO2009158446A2 (en) 2008-06-25 2009-12-30 Bristol-Myers Squibb Company Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010007561A1 (en) 2008-07-15 2010-01-21 Pfizer Limited Novel compounds active as muscarinic receptor antagonists
WO2010007552A1 (en) 2008-07-15 2010-01-21 Pfizer Limited Novel compounds active as muscarinic receptor antagonists
WO2010025202A1 (en) 2008-08-29 2010-03-04 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
ES2387474T3 (es) 2008-08-29 2012-09-24 Amgen, Inc Compuestos de piridazino-piridinona para el tratamiento de enfermedades mediadas por proteína cinasa
WO2010038428A1 (ja) 2008-09-30 2010-04-08 武田薬品工業株式会社 タキサン系抗がん剤の置き換え薬
EP2206534A1 (de) 2008-10-09 2010-07-14 c-a-i-r biosciences GmbH Dibenzocycloheptanonderivate und pharmazeutische Mittel, welche diese Verbindungen enthalten
US8772481B2 (en) 2008-10-10 2014-07-08 Amgen Inc. Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof
US8497269B2 (en) 2008-10-10 2013-07-30 Amgen Inc. Phthalazine compounds as p38 map kinase modulators and methods of use thereof
US20110263647A1 (en) 2009-01-15 2011-10-27 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
EP2393492A1 (en) 2009-02-09 2011-12-14 Boehringer Ingelheim International GmbH New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
JP2012518003A (ja) 2009-02-13 2012-08-09 バーテックス ファーマシューティカルズ インコーポレイテッド ２−（２，４−ジフルオロフェニル）−６−（１−（２，６−ジフルオロフェニル）ウレイド）ニコチンアミドの固体形態
EP2396302A2 (en) 2009-02-13 2011-12-21 Vertex Pharmceuticals Incorporated Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides)
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
PE20120655A1 (es) 2009-02-17 2012-06-07 Chiesi Farma Spa Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map)
WO2010120963A1 (en) 2009-04-16 2010-10-21 Bristol-Myers Squibb Company Tablet formulation for p38 inhibitor and method
CN102574838B (zh) 2009-05-05 2014-07-02 默沙东公司 作为p38激酶抑制剂的吡咯并[2,3-c]吡啶衍生物
EP2470534A4 (en) 2009-08-24 2013-02-27 Merck Sharp & Dohme INHIBITION OF JAK BLOCKES TOXICITIES ASSOCIATED WITH INTERFERENCE RNA
CN104043126A (zh) 2009-10-22 2014-09-17 霍夫曼-拉罗奇有限公司 轴突变性的调节
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
WO2011083387A1 (en) 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
EA022360B1 (ru) 2010-03-24 2015-12-30 Онконова Терапьютикс, Инк. Композиции и способы для профилактики и лечения ран
US9060967B2 (en) 2010-03-26 2015-06-23 Onconova Therapeutics, Inc Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
SG186855A1 (en) 2010-06-28 2013-02-28 Merck Patent Gmbh 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
JP5886842B2 (ja) 2010-07-05 2016-03-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナーゼ誘発疾患の処置に有用なビピリジル誘導体
WO2012031057A1 (en) 2010-09-01 2012-03-08 Bristol-Myers Squibb Company Bms- 582949 for the treatment of resistant rheumatic disease
RU2013129860A (ru) 2010-11-29 2015-01-10 Дженентек, Инк. Способы выявления нейродегенеративных заболеваний или нарушений
AR083868A1 (es) 2010-12-03 2013-03-27 Lilly Co Eli Compuestos de oxazol[5,4-b]piridin-5-ilo
AU2012224979B2 (en) 2011-03-09 2017-01-19 Merck Patent Gmbh Pyrido [2, 3 - b] pyrazine derivatives and their therapeutical uses
DK3081568T3 (da) 2011-05-09 2020-02-24 Eip Pharma Llc Sammensætninger og fremgangsmåder til behandling af alzheimers sygdom
CN103562198B (zh) 2011-06-10 2016-08-24 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
EP2729146B1 (en) 2011-07-08 2017-03-08 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
SG11201401795XA (en) 2011-11-11 2014-09-26 Lilly Co Eli Combination therapy for ovarian cancer
WO2013086002A1 (en) 2011-12-05 2013-06-13 Cellworks Research India Private Limited Compositions, process of preparation of said compositions and method of treating cancer
WO2013083606A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Kinase inhibitors
ES2612259T3 (es) 2011-12-09 2017-05-16 Chiesi Farmaceutici S.P.A. Inhibidores de cinasa
US9458154B2 (en) 2011-12-09 2016-10-04 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN117736134A (zh) 2012-01-12 2024-03-22 耶鲁大学 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
UA113302C2 (xx) 2012-03-01 2017-01-10 Кристалічний поліморф 1-(3-трет-бутил-1-п-толіл-1h-піразол-5-іл)-3-(5-фтор-2-(1-(2-гідроксіетил)-1н-індазол-5-ілокси)бензил)сечовини гідрохлориду
ES2605942T3 (es) 2012-03-20 2017-03-17 Mereo Biopharma 1 Limited Uso de un derivado de pirazol en el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva crónica
JP6267193B2 (ja) 2012-05-22 2018-01-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換ジピリジルアミン類及びそれらの使用
EP2858630A4 (en) * 2012-06-07 2016-02-24 Harvard College NANOTHERAPEUTIC PRODUCTS FOR DRUG TARGETING
CA2879222A1 (en) * 2012-07-17 2014-01-23 Glaxosmithkline Llc Nicotinamide derivate in the treatment of acute coronary syndrome
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
US20150225373A1 (en) 2012-08-29 2015-08-13 Respivert Limited Kinase inhibitors
US9783556B2 (en) 2012-08-29 2017-10-10 Respivert Limited Kinase inhibitors
EP2890460B1 (en) 2012-08-29 2017-02-22 Respivert Limited Kinase inhibitors
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
US9155747B2 (en) 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
US9732063B2 (en) 2012-11-16 2017-08-15 Respivert Limited Kinase inhibitors
JP6042995B2 (ja) 2012-11-30 2016-12-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害薬
US9370527B2 (en) 2012-12-28 2016-06-21 The Regents Of The University Of Michigan Amelioration of intestinal fibrosis and treatment of Crohn's disease
EP2961744B1 (en) 2013-02-27 2017-06-28 Array Biopharma, Inc. Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
EP2970190A1 (en) 2013-03-14 2016-01-20 Respivert Limited Kinase inhibitors
GB201305714D0 (en) 2013-03-28 2013-05-15 Ucl Business Plc Method
CA2907566C (en) * 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
TWI641592B (zh) 2013-04-02 2018-11-21 英商瑞斯比維特有限公司 激酶抑制劑
WO2014181213A1 (en) 2013-05-10 2014-11-13 Pfizer Inc. Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
US9359354B2 (en) 2013-06-06 2016-06-07 Chiesi Farmaceutici S.P.A. Kinase inhibitors
KR20160016973A (ko) 2013-06-06 2016-02-15 키에시 파르마슈티시 엣스. 피. 에이. P38 - map 키나아제 억제제로서 [1, 2, 4] 트리아졸로 [4, 3 - a] 피리딘의 유도체
RU2015151886A (ru) 2013-06-06 2017-06-08 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Ингибиторы киназ
US9707219B2 (en) 2013-07-10 2017-07-18 Glaxosmithkline Intellectual Property (No.2) Limited Losmapimod for use in treating glomerular disease
US9918989B2 (en) 2013-07-12 2018-03-20 The Regents Of The University Of California Combination therapies for malaria
US9814728B2 (en) * 2013-09-20 2017-11-14 Saint Louis University Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)
EP3069732B1 (en) * 2013-11-14 2023-07-12 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
AU2014369449B2 (en) 2013-12-20 2018-07-05 Oxular Acquisitions Limited Urea derivatives useful as kinase inhibitors
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
KR102413704B1 (ko) 2014-02-14 2022-06-24 레스피버트 리미티드 항염증성 화합물로서의 방향족 헤테로사이클릭 화합물
AU2015220873A1 (en) 2014-02-19 2016-08-11 H. Lundbeck A/S 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's disease
US20230190750A1 (en) 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
WO2015191996A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CN114010641A (zh) 2014-07-09 2022-02-08 爱普制药有限责任公司 用于治疗神经病症的方法
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
EP3201189A1 (en) 2014-10-01 2017-08-09 Respivert Limited N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors
WO2016049677A1 (en) 2014-10-03 2016-04-07 The Walter And Eliza Hall Institute Of Medical Research Method of treating cancer
WO2016066687A1 (en) * 2014-10-30 2016-05-06 Glaxosmithkline Intellectual Property (No.2) Limited Losmapimod for treating copd
WO2016114655A1 (en) * 2015-01-12 2016-07-21 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
US10538763B2 (en) * 2015-01-16 2020-01-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of DUX4
EP3253874B1 (en) * 2015-02-06 2022-03-23 Association Institut de Myologie Treatment of facioscapulohumeral dystrophy
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
JP6701225B2 (ja) 2015-03-09 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三環式ｄｌｋ阻害剤及びその使用
WO2016154329A2 (en) * 2015-03-24 2016-09-29 The Trustees Of The University Of Pennsylvania P38 map kinase inhibitors for treating friedreich's ataxia
JP2016193870A (ja) 2015-04-01 2016-11-17 国立大学法人広島大学 慢性骨髄性白血病治療剤
US9968604B2 (en) 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
CN107921106B (zh) * 2015-05-20 2023-09-08 住友制药株式会社 Wt1抗原肽和免疫调节剂的组合用途
KR20180014778A (ko) * 2015-06-03 2018-02-09 트리아스텍 인코포레이티드 제형 및 이의 용도
WO2016198698A2 (en) 2015-06-12 2016-12-15 Cnic Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii P38 inhibitors for the treatment and prophylaxis of liver cancer
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
WO2017075013A1 (en) 2015-10-26 2017-05-04 Eip Pharma, Llc Methods and compositions for recovery from stroke
US9427439B1 (en) 2015-10-26 2016-08-30 Eip Pharma, Llc Methods and compositions for recovery from stroke
EP3383867B1 (en) 2015-12-03 2021-04-14 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP3394058B1 (en) 2015-12-23 2020-10-14 Chiesi Farmaceutici S.p.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
WO2017110093A1 (ja) 2015-12-24 2017-06-29 学校法人同志社 ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用
US20190125735A1 (en) 2015-12-29 2019-05-02 Board Of Regents, The University Of Texas System Inhibition of p38 mapk for the treatment of cancer
AU2017213796A1 (en) * 2016-02-01 2018-09-20 President And Fellows Of Harvard College Small molecules for mouse satellite cell proliferation
WO2017134053A1 (en) 2016-02-04 2017-08-10 Chiesi Farmaceutici S.P.A. Pyrazole derivatives as phosphoinositide 3-kinases inhibitors
PE20190376A1 (es) 2016-06-08 2019-03-08 Support Venture Gmbh Combinaciones farmaceuticas para el tratamiento del cancer
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
US11123349B2 (en) 2017-02-15 2021-09-21 The University Of Melbourne Method of treatment
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US20200297696A1 (en) 2017-11-21 2020-09-24 Saint Louis University P38 inhibitors for the treatment of fshd
US20220017908A1 (en) 2018-11-20 2022-01-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease
US20220079951A1 (en) * 2018-12-20 2022-03-17 Saint Louis University Bet inhibitors for modulating dux4 expression in fshd
CN114144230B (zh) 2019-03-15 2024-04-23 弗尔康医疗公司 作为eed和prc2调节剂的大环唑并吡啶衍生物
WO2022056266A2 (en) * 2020-09-11 2022-03-17 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use

Also Published As

Publication number Publication date
RS63581B1 (sr) 2022-10-31
EP4159212A1 (en) 2023-04-05
NZ765534A (en) 2021-04-30
BR112020006169A2 (pt) 2020-10-20
CA3127373A1 (en) 2019-04-11
CA3128468A1 (en) 2019-04-11
AU2018346712A1 (en) 2020-04-09
EP3691620A1 (en) 2020-08-12
IL273657A (en) 2020-05-31
CA3077499A1 (en) 2019-04-11
EP3691620B1 (en) 2022-07-27
CN114748622A (zh) 2022-07-15
US11479770B2 (en) 2022-10-25
JP2024012295A (ja) 2024-01-30
TW201924676A (zh) 2019-07-01
SG10202110259QA (en) 2021-10-28
HRP20221196T1 (hr) 2022-12-09
CN111601593B (zh) 2022-04-15
MX2020003594A (es) 2021-04-07
PT3691620T (pt) 2022-10-06
CL2020000913A1 (es) 2020-09-25
JP2023113691A (ja) 2023-08-16
KR20200066655A (ko) 2020-06-10
JP7012152B2 (ja) 2022-02-10
IL273589B (en) 2020-11-30
US20200383963A1 (en) 2020-12-10
CA3077499C (en) 2021-09-21
ES2927715T3 (es) 2022-11-10
HUE060024T2 (hu) 2023-01-28
CO2020005351A2 (es) 2020-05-15
AU2018346712B2 (en) 2021-04-01
PH12020550195A1 (en) 2020-12-07
ECSP20024210A (es) 2020-07-31
PL3691620T3 (pl) 2022-11-21
PH12020550215A1 (en) 2021-02-15
TWI793191B (zh) 2023-02-21
CL2020000911A1 (es) 2021-02-19
NZ762856A (en) 2020-07-31
JP2020536884A (ja) 2020-12-17
IL273589A (en) 2020-05-31
UY37918A (es) 2019-04-30
US11291659B2 (en) 2022-04-05
US20230257743A1 (en) 2023-08-17
JP2021501130A (ja) 2021-01-14
CA3078232A1 (en) 2019-04-11
CN114748622B (zh) 2024-09-24
JP2022031915A (ja) 2022-02-22
US20220133704A1 (en) 2022-05-05
CN114732910B (zh) 2024-08-23
MX2020003961A (es) 2020-09-22
SG11202003035SA (en) 2020-04-29
DK3691620T3 (da) 2022-10-03
CN114732910A (zh) 2022-07-12
CN111868237A (zh) 2020-10-30
WO2019071147A1 (en) 2019-04-11
US20200332291A1 (en) 2020-10-22
ZA202002315B (en) 2021-07-28
US20220282254A1 (en) 2022-09-08
CL2020001719A1 (es) 2020-09-11
KR20200067170A (ko) 2020-06-11
WO2019071144A1 (en) 2019-04-11
AU2018346709A1 (en) 2020-04-16
BR112020006677A2 (pt) 2020-10-06
LT3691620T (lt) 2022-09-26
CN111601593A (zh) 2020-08-28
CO2020005417A2 (es) 2020-07-31

Similar Documents

Publication Publication Date Title
US20230257743A1 (en) Use of p38 inhibitors to reduce expression of dux4
US10407734B2 (en) Compositions and methods of using transposons
HU229263B1 (en) The use of pharmaceutical compositions containing 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
US9198910B2 (en) Methods for the treatment of cancer
AU2014246667A1 (en) Methods of treating diseases characterized by excessive Wnt signalling
Wu et al. Depletion of extracellular signal-regulated kinase 1 in mice with cardiomyopathy caused by lamin A/C gene mutation partially prevents pathology before isoenzyme activation
KR20190103154A (ko) 암의 치료법을 위한 brd4 억제제 및 항폴레이트의 조합
JP2022554258A (ja) Ａｌｋ陰性癌および形質細胞媒介性疾患の治療のためのａｌｋ阻害剤
CN109312407A (zh) 用于癌症的诊断和治疗方法
EP3283127B1 (en) Compositions and methods for xi chromosome reactivation
US20220218734A1 (en) Combinations of therapeutic agents for treating uveal melanoma
TW202021626A (zh) 辨識有可能受益於以端粒酶抑制劑治療之患者的方法
WO2014039696A9 (en) Transposable elements, tdp-43, and neurodegenerative disorders
Liao et al. Telomeres: dysfunction, maintenance, aging and cancer
Long et al. Resistance to PRMT5-targeted therapy in mantle cell lymphoma
JP7062292B2 (ja) リン脂質ヒドロペルオキシド依存性細胞死の抑制剤及びリン脂質ヒドロペルオキシド依存性細胞死が関連する疾患の予防又は治療剤
US20230374505A1 (en) Human XIST Antisense Oligonucleotides for X Reactivation Therapy
JP2019517552A (ja) 発がんにおける末端ｒｎａウリジル化およびｒｎａ代謝回転の新規役割
JP6646303B2 (ja) リン脂質ヒドロペルオキシド依存性細胞死の検出方法及びキット、リン脂質ヒドロペルオキシド依存性細胞死の抑制剤、並びに心不全又は不整脈性突然死の予防又は治療剤
JP6646302B2 (ja) リン脂質ヒドロペルオキシド依存性細胞死の検出方法及びキット、リン脂質ヒドロペルオキシド依存性細胞死の抑制剤、並びに心不全又は不整脈性突然死の予防又は治療剤
JP6646304B2 (ja) リン脂質ヒドロペルオキシド依存性細胞死の検出方法及びキット、リン脂質ヒドロペルオキシド依存性細胞死の抑制剤、並びに心不全又は不整脈性突然死の予防又は治療剤
JP6637092B2 (ja) リン脂質ヒドロペルオキシド依存性細胞死の検出方法及びキット、リン脂質ヒドロペルオキシド依存性細胞死の抑制剤、並びに心不全又は不整脈性突然死の予防又は治療剤
EA046703B1 (ru) Ингибиторы киназы р38 снижают экспрессию dux4 и последующих генов для лечения fshd
JP2023510297A (ja) アルツハイマー病の治療
JP6436654B2 (ja) リン脂質ヒドロペルオキシド依存性細胞死の検出方法及びキット、リン脂質ヒドロペルオキシド依存性細胞死の抑制剤、並びにリン脂質ヒドロペルオキシド依存性細胞死が関連する疾患の予防又は治療剤

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200429

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210623

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230411

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/6883 20180101ALI20231003BHEP

Ipc: A61K 31/513 20060101ALI20231003BHEP

Ipc: A61K 31/506 20060101ALI20231003BHEP

Ipc: A61K 31/454 20060101ALI20231003BHEP

Ipc: G01N 33/68 20060101ALI20231003BHEP

Ipc: G01N 33/50 20060101ALI20231003BHEP

Ipc: C07K 14/47 20060101ALI20231003BHEP

Ipc: A61K 31/00 20060101ALI20231003BHEP

Ipc: A61K 31/437 20060101ALI20231003BHEP

Ipc: A61K 31/4418 20060101ALI20231003BHEP

Ipc: A61K 31/4439 20060101ALI20231003BHEP

Ipc: A61K 31/416 20060101ALI20231003BHEP

Ipc: A61K 31/496 20060101ALI20231003BHEP

Ipc: A61K 31/519 20060101ALI20231003BHEP

Ipc: A61K 31/53 20060101ALI20231003BHEP

Ipc: A61K 31/5377 20060101ALI20231003BHEP

Ipc: G01N 33/15 20060101ALI20231003BHEP

Ipc: A61P 21/00 20060101ALI20231003BHEP

Ipc: C12N 9/12 20060101AFI20231003BHEP